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8ABSTRACT
Slowness, stiffness, tremor, and postural instability are the cardinal symptoms of
Parkinson’s disease (PD). Since these symptoms are not specific to PD the diagnosis
may be uncertain in early PD. Etiology and pathogenesis of PD remain unclear, and
there is no neuroprotective treatment. Genetic findings are expected to reveal
metabolic routes in PD pathogenesis and thereby eventually lead to therapeutic
innovations.
The starting point of this thesis was to study the usefulness and accuracy of 123I-?-CIT
SPECT in the diagnosis of PD in a consecutive clinic-based material including various
movement disorder patients. 123I-?-CIT SPECT could distinguish PD from essential
tremor, drug-induced parkinsonism, dystonia, psychogenic parkinsonism, and most
cases from vascular parkinsonism, but ?-CIT uptake in Parkinson plus syndromes and
DLB was similar to that in PD. 123I-?-CIT SPECT was 100% sensitive and specific in the
diagnosis of PD in patients younger than 55 years but less specific in older patients,
due to differential distribution of the above conditions in the younger and older age
groups. 123I-?-CIT SPECT correlated with symptoms and was able to detect a bilateral
nigrostriatal defect in patients whose disease was still in unilateral stage. In addition
to its use as a differential diagnostic aid, 123I-?-CIT SPECT may also be used to detect
PD early, even pre-symptomatically in at-risk individuals.
Subsequently we started a genetic project (II-V) to identify genetic risk factors for
sporadic PD using candidate gene approach in a case-control setting, including 147
sporadic PD patients and 137 spouses as controls. 123I-?-CIT SPECT was used as a
part of the patient collection to the genetic studies.
We found no association between PD and parkin or DJ-1, genes underlying autosomal
recessive parkinsonism. The functional Val158Met polymorphism, which affects the
catalytic effect of COMT enzyme, and another coding polymorphism in COMT were not
associated with PD in our patient material.
The APOE ?2/3/4 polymorphism modifies risk for Alzheimer’s disease and prognosis of
e.g. brain trauma. APOE promoter and enhancer region polymorphisms –219G/T and
+113G/C, and APOE ?3 haplotypes, have also been shown to modify risk of
9neuropathologically verified Alzheimer’s disease but have not been reported in PD.  In
our study, no association was found between PD and the APOE ?2/3/4 polymorphism,
–219G/T, +113G/C and the e3 haplotypes.
A genetic association was found with a polymorphic CAG-repeat in POLG1, the gene
encoding the catalytic subunit of mitochondrial polymerase gamma, in both Finnish
and North American PD patients. This CAG-repeat encodes a polyglutamine (polyQ)
tract, the two most common lengths of which are 10Q (86-90%) and 11Q. In our
Finnish material, the rarer non-10Q or non-11Q length variants (6Q-9Q, 12-14Q,
4R+9Q) were increased in frequency in patients compared to the spouse controls
(10% vs. 3.5 %, p=0.003), and population controls (p=0.001). Therefore, we
performed a replication study in a larger set of 652 North American PD patients and
292 controls. Non-10/11Q alleles were more common in US PD patients compared to
the controls but the difference did not reach statistical significance (p=0.07). This
larger data suggested that our original definition of variant length allele might need
reconsideration. Most studies have defined 10Q as the only reference allele. Alleles
other than 10Q, including also 11Q (non-10Q), were significantly more common in
patients compared to the controls (17.3% vs. 12.3 %, p= 0.005). This significant
association of non-10Q length variants and PD was seen also seen when compared to
a larger set of 1541 literature controls (17.3 % vs. 12.8 %, p=0.00005).  Our results
suggest that POLG1 polyQ alleles other than 10Q may predispose to PD.
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INTRODUCTION
In 1817 a British physician, James Parkinson, first described a disease in his
publication “An essay on the shaking palsy“, based on his observations of six
patients: "Involuntary tremulous motion, with lessened muscular power, in
parts not in action and even when supported; with a propensity to bend the
trunk forward, and to pass from a walking to a running pace; the senses and
intellects being uninjured."  Later this disease was named Parkinson’s disease
(PD) after him.
Tremor, slowness and poverty of movement (brady- and hypokinesia), and
stiffness (rigidity) are three major motor symptoms of PD. Problems with
controlling balance and posture follow. The patients’ motor ability declines in
progressive course. Now we also know that “intellects being uninjured” is not
true for around 30% of PD patients. Autonomic dysfunction, sleep
disturbances, and depression are other possible non-motor symptoms.
The clinical picture of parkinsonism is not specific to PD, and therefore, the
diagnosis may be difficult in the early phases of the disease despite strict
clinical criteria1, 2. SPECT imaging of the dopaminergic system has been
proposed to help in the differential diagnosis of PD.
PD is a neurodegenerative disease with an average age-of-onset around 60
years. Thus, with increasing life expectancy, the number of PD patients is
expected to increase, even double during the next two decades 3. Considering
the remarkable PD-related disability, this is also an increasing challenge to
society.
What causes PD remains unclear. PD typically occurs sporadically, and
primarily environmental factors, such as pesticides or heavy metals, have been
suspected to cause PD. Rare hereditary forms of PD exist. Mutations in eight
genes have been so far identified as a cause of hereditary parkinsonism
(OMIM, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=168600 ).
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Genealogical and twin studies support the role of a genetic component also in
the predisposition to the more common apparently sporadic PD4. The general
view is that both environmental and genetic factors modify the predisposition
to PD.
Genetic findings have revealed and are hoped to reveal metabolic routes in the
so far poorly known pathogenesis of PD. Knowing the pathogenesis is needed
to develop specific neuroprotective, maybe even preventive therapies. So far
only symptomatic medication is available.
12
REVIEW OF THE LITERATURE
1. WHAT IS PARKINSON’S DISEASE?
1.1 Epidemiology of PD
PD is considered the second most common neurodegenerative disease after
Alzheimer’s disease5. PD is slightly more common in men 6. Incidence rates
reported for PD range from 8 to 18 per 100 000. PD might be less common in
black and Asian people5. In industrialized countries the overall prevalence of PD
is generally estimated about 0.3% in the entire population and 1.0% in
population over 60 or 1.6% in population over 65 years of age 7. PD is clearly
an age-related disease: it is rare before age 50 years and prevalence increases
with age, being up to 4% in age group 85-94 years 5, 8. In Finland there are
approximately 10 000 PD patients9. Along with increased life expectancy the
number of PD patients has been estimated to double in the next 20 years3.
 1.2 Clinical manifestations and disease progression of PD
Parkinsonism is an entity of symptoms comprising of tremor, rigidity,
hypokinesia, and postural instability. Idiopathic PD is the most common cause
of parkinsonism. In PD, parkinsonism is often accompanied by a broader
spectrum of other symptoms. The cardinal motor symptoms typically present
initially asymmetrically. Tremor is usually resting tremor with a 4-6 Hz
frequency beginning usually in either hand and spreading later to other limbs.
Chin and lips may also be affected, and postural or action tremor may also
occur.
Hypokinesia (smallness of movement) and bradykinesia (slowness) contribute
to the slow shuffling gait, lost arm swing when walking, poor manual dexterity,
small handwriting, hypomimia (loss of facial expression), monotonic silent
speech, and dysphagia.  Rigidity implies an increase in muscle tone, leading to
a resistance to passive movement throughout the range of motion and
13
presents either as “cogwheeling” or smooth lead pipe type stiffness both in
limb and later in axial muscles.  Postural instability, falls and freezing usually
manifest at later stage in PD patients.
Compared with healthy age-matched controls, PD patients have significantly
more autonomic symptoms 10. Autonomic system involvement manifests as
cardiovascular (e.g. orthostatic hypotension), thermoregulatory,
gastrointestinal (e.g. constipation, sialorrhea), urinary problems, and sexual
dysfunction. Autonomic symptoms are present in virtually all PD patients at
some stage of disease and contribute to the disease burden 11. Older age,
greater motor symptom severity and higher doses of dopaminergic medication
are related with more autonomic problems 10.
Depressive disorders are estimated to affect up to 50% of PD patients and
depression may be an early symptom of PD 12. Psychotic symptoms such as
visual hallucinations occur at later stages of PD, partly due to the disease
process and partly due to dopaminergic medication, more often in patients
with cognitive decline. Sleep disturbances, e.g. insomnia, daytime sleepiness,
or REM sleep behavioural disorder, are common in PD patients 11.
Estimates of the prevalence of dementia or cognitive decline in PD have
increased over the last years. Incidence of dementia in these patients is up to
six times that in healthy people. Typically PD dementia affects about 30 % of
patients and is characterized by impairment in attention, executive and visuo-
spatial functions 13, 14. Akinetic-rigid form of PD and older age are related to
higher risk of dementia. In a recent longitudinal cohort study, 140  (60 %) of
initial 233 PD patients developed dementia after a 12-year study period 15. The
cumulative incidence of dementia increases with age and duration of PD and,
conditional on survival, increases to 80%-90% by age 90 years 15.
The clinical onset of PD is preceded by a pre-symptomatic phase of several
years: nigral neuron loss is estimated to be 60% at the onset of symptoms 16,
17. Before the onset of motor parkinsonism, some pre-motor symptoms may be
present, including constipation, depression, sleep disturbances (especially REM
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sleep behaviour disorder), and hypo-osmia 18, all logical considering the
neuropathological progression of PD described in the next chapter.
The clinical course is progressive with highly variable rate of progression. On
average, functional decline is more rapid and mortality higher in patients who
predominantly present with non-tremor symptoms of PD, i.e. gait disturbance,
akinetic-rigid syndrome, and cognitive decline 19, 20.
1.3 Neuropathology in PD
The classical pathological hallmarks of PD are the accumulation of
intraneuronal cytoplasmic inclusions called Lewy bodies (LB) and Lewy neurites
(thread-like protein aggregates in neuronal processes), and loss of the
dopaminergic neurons of substantia nigra (SN) pars compacta projecting
primarily to the putamen.
Lewy bodies were first seen and linked to Parkinson’s disease ("paralysis
agitans") in 1912 by the neurologist Frederic Lewy21. LB’s are spherical
eosinophilic cytoplasmic protein aggregates composed of ?-synuclein and
numerous other proteins: parkin, ubiquitin, synphilin and neurofilaments. The
role of LB’s in neuronal death is controversial. LB’s are found in all affected
brain regions but they are not specific to PD: they are also found in dementia
with Lewy bodies (DLB), Alzheimer’s disease, MSA, Hallervorden-Spatz disease
and as an incidental pathological finding also in neurologically healthy people
of advanced age22, 23. Recent neuropathological studies indicate that
Alzheimer’s disease, PD and DLB share many neuropathological features,
indicating that at least partially shared neurodegenerative mechanisms operate
in these disorders24-26.
The loss of striatal dopaminergic neurons underlies the cardinal motor
symptoms, but neurodegeneration extends beyond that. Neurodegeneration
and LB formation are found in noradrenergic (locus coeruleus), serotonergic
(raphe), and cholinergic (nucleus basalis of Meynert, dorsal motor nucleus of
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vagus) systems, and in the cerebral cortex, olfactory bulb, and autonomic
nervous system 17. A recent staging procedure for the PD-associated brain LB
pathology proposes that the process begins at two sites in the brain and
spreads in a topographically predictable sequence in six stages. It has even
been suggested that the disease may begin in the enteric nervous system and
extend secondarily to the brain 27, a hypothesis still awaiting definite proof. It
is unclear at which stage the autonomic nervous system is injured 28. In stages
1 and 2, LB pathology is confined to the medulla oblongata, initially the dorsal
motor nucleus of the glossopharyngeal and vagal nerves, and pontine
tegmentum (including raphe nuclei, formatio reticularis) and olfactory bulb.
Midbrain, particularly substantia nigra becomes involved in stage 3, and during
stages 3-4 the disease is suggested to become clinically manifest 29. In the
final stages 5-6 the LB pathology spreads in the neocortex 29.
Table 1.
Clinico-pathological correlations of PD stages
Clinical phase Pathology
Preclinical Medulla oblongata, pontine tegmentum, olfactory bulb, autonomic? (Stages1-2)
Early- moderate PD Medulla oblongata, pontine tegmentum, olfactory bulb, autonomic?, substantia
nigra (Stages 3-4)
Severe PD, PDD Medulla oblongata, pontine tegmentum, olfactory bulb, autonomic, substantia
nigra, cortex (Stages 5-6)
Simplified from 28, 30, 31.
    PDD= PD with dementia
1.3.1 Selective neuronal vulnerability
An important question in elucidating the pathogenesis of a disease is the
selective vulnerability of specific cell types.  Neuronal vulnerability or
resistance may be affected by cell size and localization, metabolism of disease-
specific proteins and a repertoire of signal transduction pathways and stress
resistance mechanisms 32. Because dysfunction and death of neurons affect
adversely both the pre- and post-synaptic neurons they communicate with, the
patterns of progression of neuronal degeneration are often domino-like 32.
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In PD the degenerating cell population is mostly, but not exclusively as
discussed above, the dopaminergic nigrostriatal neurons. For PD, preferential,
instead of selective, neuronal vulnerability is a better expression.
Even though the degeneration of the dopaminergic neurons of the SN pars
compacta is the most prominent feature in PD, and about 60 % of them are
already lost at the time of diagnosis 16, not all brain dopaminergic neurons are
equally affected in PD: in post-mortem PD brains 40-60% of the mesolimbic
/mesocortical projections from the ventral tegmental area are lost 33, 34, but
the dopaminergic neurons from nucleus arcuatus of the hypothalamus that
regulate anterior pituitary secretion are not lost 35.
2. DIAGNOSIS OF PD
2.1 Clinical diagnosis
Diagnosing PD may be challenging in the early phases of PD because of the
variability of the PD phenotype and the significant overlap between other
parkinsonian syndromes. No clinical sign or symptom is specific to PD.
The diagnosis of PD is based on findings of parkinsonism on neurological
examination and exclusion of other causes for parkinsonism using neurological
examination, medical history, trial of antiparkinsonian drugs, and follow-up.
Neuroimaging, neurophysiological studies or laboratory tests are usually not
needed. The most commonly used diagnostic criteria for PD are the United
Kingdom Parkinson’s Disease Society Brain Bank clinical diagnostic criteria
presented in table 2 1.
Post-mortem studies have found error rates of PD diagnosis as high as 24% 1.
In another clinicopathological study, Rajput et al found that clinical diagnosis
within 5 years of disease onset was correct in 65% of cases. After a mean
duration of 12 years, the final diagnosis of PD by the clinician was confirmed at
autopsy in 76% of cases 36. With strict criteria the accuracy of a clinical
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diagnosis of the disease can be improved significantly, but up to 10% of
patients diagnosed with PD in life will still have to be reclassified at autopsy 2.
Table 2. UK PD Society Brain Bank criteria for idiopathic PD (modified from 1)
INCLUSION CRITERIA SUPPORTIVE CRITERIA EXCLUSION CRITERIA
Hypokinesia Asymmetric onset Repeated head trauma
AND at least 1 of the
following
Progression of the disease Repeated stroke
Rigidity Persistent asymmetry History of encephalitis
4-6 Hz resting tremor Resting tremor Ocylogyric crises
Postural instability Good response to L-dopa Neuroleptic therapy at onset
L-dopa-induced dyskinesia Persistent remission
Persistent (?5 years) response
to L-dopa
Purely unilateral symptoms 3 years
after onset
Long clinical course (?10 years) More than 1 relative with
parkinsonism *
Supranuclear gaze palsy
Cerebellar signs
Early severe autonomic dysfunction
Early severe dementia
Babinski sign
Brain tumor or hydrocephalus
Lack of response to L-dopa
Exposure to MPTP
* hereditary parkinsonian syndromes are not classified as idiopathic PD here
2.2  The most important differential diagnoses
Symptoms of parkinsonism are also caused by other mechanisms than PD,
with or without nigrostriatal pathology. Early falls, poor response to L-dopa,
rapid progression of symptoms, disturbance of eye movements, problems with
swallowing or speech, pyramidal signs and early autonomic involvement
indicate diagnosis other than idiopathic PD 37.
Structural imaging of the brain with CT or MRI is normal in PD, but may have
value in excluding other causes such as vascular parkinsonism (VP), tumors,
normal pressure hydrocephalus (NPH). MRI may also be helpful in
differentiating PD from Parkinson plus (P+) syndromes as in these several
structural MRI changes have been described: putaminal, pontine, and middle
cerebral peduncle atrophy and T2 signal changes in the basal ganglia and
18
brainstem in multisystem atrophy (MSA), midbrain atrophy in progressive
supranuclear palsy (PSP), and asymmetric frontoparietal atrophy in
corticobasal degeneration (CBD) 38, 39. Clinical neurophysiology is of little value
in diagnosing parkinsonism in routine clinical practice 40. Laboratory testing is
also of little value, except in excluding Wilson’s disease, or SCA-2, SCA-3 or
SCA-17 in rare cases 40.
In P+ syndromes parkinsonism occurs with other features.
PSP, neuropathologically a tauopathy, is the most common P+ syndrome. In
PSP loss of vertical eye movements and cognitive decline accompany akinetic-
rigid type parkinsonism and early postural instability 41.  CBD is another
tauopathy, the special clinical features of which are marked persistently
asymmetric rigidity of the limbs, especially upper limb, “alien limb” sign,
dysarthria, dysphasia, sensory symptoms and apraxia 42. Multiple system
atrophy (MSA) was earlier considered as three different diseases: Shy-Drager
syndrome, striatonigral degeneration, and sporadic olivopontocerebellar
atrophy. At present, they are categorized as MSA-P (patients with
predominantly parkinsonian features) or MSA-C (patients with predominantly
cerebellar ataxia), depending on the predominant feature when the patient is
evaluated.  In MSA, marked autonomic dysfunction presents early particularly
as orthostatic hypotension and collapses; in PD autonomic symptoms usually
occur later. Also postural instability shows up earlier in MSA than in PD.
Parkinsonism is usually of akinetic-rigid type, and response to L-dopa is poor
39.  In dementia with Lewy Bodies (DLB) early progressive dementia, cognitive
fluctuation, hallucinations, marked sensitivity to neuroleptics combine with
parkinsonian symptoms 43. The neuropathological features of DLB and PD
overlap: both have LB’s but their distribution is different 31.
False PD diagnoses are most commonly essential tremor (ET) 40, which is
characterized by presence of bilateral, largely symmetrical, postural or kinetic
tremor that affects the hands and forearms and is visible and persistent.
Bradykinesia, rigidity, and postural instability are not part of ET 44. Difficult
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diagnostic situations arise when an otherwise typical case of ET is associated
with rest tremor (10% of cases) or when the tremor is unilateral 45, 46. The
presence of family history and relief by alcohol strongly favour the diagnosis of
ET 44.
Secondary parkinsonism may result from drugs, cerebrovascular disease,
trauma, infections (post-encephalitic parkinsonism) and toxins (e.g.
manganese, carbon monoxide, MPTP). Drug-induced parkinsonism  (DIP) is
usually caused by antipsychotics, but also other drugs, e.g. metoclopramide,
calcium channel blockers, lithium, and natriumvalproate may provoke
parkinsonian symptoms. Tremor is less common than hypokinesia and rigidity,
and the symptoms are typically symmetrical. DIP is in most cases reversible
after discontinuation of the causative drug 47. Vascular parkinsonism (VP) is a
controversial entity. It is often characterised by widespread bilateral deep
lacunar white matter infarcts and typically causes a parkinsonian gait disorder
with freezing and wide-based small stepped gait (lower body parkinsonism).
Onset is usually gradual, but striatal or SN infarcts can give rise to acute onset
of contralateral parkinsonism 48, 49.
2.3 SPECT and PET imaging of the dopaminergic system in PD
As described above, the diagnosis of PD is usually clinical, but ancillary
methods may be considered for some selected problematic cases.
Dopamine transporters (DAT) are dopamine re-uptake proteins on the
presynaptic terminals of dopaminergic neurons 50, 51. Measuring DAT density
using DAT ligands and single-photon emission computed tomography (SPECT)
or positron emission tomography (PET) provides in vivo information on the
integrity of these presynaptic terminals. In PD, as the number of dopaminergic
neurons is estimated to be reduced to 30-40% at the time of diagnosis 16, DAT
density is reduced. In PD, the number of DATs per neuron may also be lower
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than normal because of the attempt to increase the amount of synaptic
dopamine by means of reducing the re-uptake 52.
 123I-?-CIT (2?-carbomethoxy-3?-(4-iodophenyl)tropane) is a cocaine
derivative and a radioligand which binds to DATs and serotonin transporters
(SERT). Striatal ?-CIT binding is mainly associated with DAT, whereas binding
in the hypothalamus and midbrain is mainly associated with SERT 53. The
binding kinetics of ?-CIT is different for SERT and DAT: uptake in the striatum
is slow, reaching a maximum approximately 16 h after tracer injection,
followed by stable binding for up to 24 h after injection in humans. Peak
uptake to the hypothalamus and midbrain is observed approximately 4h after
injection. Thus, 123I-?-CIT SPECT shows substantial striatal DAT specificity at
approximately 24 hours after injection 54.
Other available DAT SPECT tracers are FP-CIT (DATSCAN, ioflupane) and
99mTc-TRODAT-1 with different binding kinetics 55, 56. The faster kinetics of 123I-
FP-CIT allows adequate acquisition as early as 3 h following injection 57.
18F-Fluorodopa (F-dopa) PET also correlates with the number of nigrostriatal
neurons. Its uptake expresses the activity of dopa-decarboxylase and
dopamine storage capacity in the striatal nerve terminals of the dopaminergic
neurons 58. Limitation of F-dopa is that dopa-decarboxylase is up-regulated
early in the disease process. This may lead to underestimation of dopaminergic
neuron loss by F-dopa PET. Therefore, DAT binding tracer may provide more
accurate estimate of nigrostriatal degeneration 59, 60. Comparative studies show
that results of DAT imaging with SPECT correlate well with PET results 61, 62.
SPECT is more widely available than PET and less expensive.
In contrast to DATs, dopamine receptors are mainly located on the striatal
gabaergic neurons projecting to the globus pallidus. 11C-Raclopride-PET or 123I-
Epidepride- or 123I-Iodobenzamide  (IBZM) SPECT may be used for
postsynaptic dopamine receptor imaging. Dopamine receptor levels are
not reduced in PD; in early PD the level of dopamine receptors may even be
upregulated 63, 64.
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2.3.1 123I-?-CIT SPECT in PD and differential diagnoses
DAT density measured with 123I-?-CIT uptake is significantly lower in PD
compared to healthy controls 65-67. Reduction of ?-CIT uptake also correlates
with symptom severity 66, 68. ? -CIT uptake decreases also along normal ageing
in healthy controls approximately 0.8% in a year 69, or 6-10% in a decade 53,
70,71.
In patients with purely unilateral symptoms (Hoehn-Yahr stage I), the
reduction of ?-CIT uptake is more evident in the contralateral striatum but
striatal DAT density is also reduced in the ipsilateral striatum 72, 73. Reduced
DAT density has also been found in patients with REM-sleep behavioural
disorder, which is a possible pre-motor symptom of PD 74. These findings
indicate that ?-CIT SPECT can also detect preclinical PD.
In approximately 10% of patients with clinical suspicion of PD, a normal DAT
SPECT has been reported. It has been proposed that most of these SWEDDs
(Scans Without Evidence of Dopaminergic Deficit) patients have dystonic
tremor 75.
Striatal 123I-??-CIT uptake is also reduced in MSA, including the cerebellar type,
and PSP 76-79. Some studies have suggested that PD might be differentiated
from these P+ syndromes using ?-CIT SPECT, but most have failed to find a
significant difference in striatal 123I???-CIT uptake between PD and MSA or PSP.
In PD the reduction of ?-CIT uptake is most pronounced in the putamina
whereas the caudate nuclei are relatively spared, in accordance with findings of
neuropathological studies 80. In MSA and PSP the striatum might be more
uniformly affected compared to PD 77, 81-83. Also asymmetry of the reduction of
?-CIT uptake is more typical in PD compared to MSA or PSP, but this difference
has not reached statistical difference in most studies 78, 79, 82, 84.
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In addition to PSP and MSA, reduced striatal ?-CIT uptake has been reported in
dementia with Lewy bodies 85, Wilson’s disease 86, spino-cerebellar ataxia type
2 (SCA2) 87 and corticobasal degeneration 78. In contrast, striatal DAT density
as visualized by ?-CIT SPECT is normal in essential tremor 88, dopa-responsive
dystonia 89, 90 and cervical dystonia 91.
Gerschlager et al suggested vascular parkinsonism (VP) could be differentiated
from PD using ?-CIT SPECT 92. In their study, DAT density of the VP patients
was within normal range, but the results of consequent FP-CIT studies on DAT
density in VP patients have been conflicting 93, 94
?
?-CIT SPECT in drug-induced parkinsonism (DIP) has not been reported.
Mostly normal FP-CIT uptake indices in small groups of patients have been
reported, but in some patients with irreversible DIP diminished DAT density
has been found, suggesting possible exacerbation of underlying
neurodegenerative parkinsonism in these patients 95-97. In patients with tardive
dyskinesia, FP-CIT uptake is normal 98.
Results of other DAT SPECT ligands are parallel to those of ?-CIT in PD and
differential diagnoses.
2.3.2   SPECT and PET imaging in genetic forms of parkinsonism
Patients with parkin (PARK2)-related parkinsonism seem to have severe and
more symmetric reduction in striatal DAT density than in PD, as measured with
FP-CIT SPECT 99. In PINK1-related disease, F-dopa PET and DAT SPECT
findings are similar to those of PD 100, 101. However, both dopaminergic neuron
loss and normal-range DAT densities have been reported in heterozygous
PINK1 mutation carriers 100, 101. In patients with DJ-1 mutation, DAT density is
in the range of idiopathic PD 102.
F-dopa PET in patients with AD parkinsonism caused by mutations in SNCA
(PARK1) or LRRK2 (PARK8) demostrates a similar degree and pattern of
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nigrostriatal degeneration as in idiopathic PD 103, 104. Thus, the nigrostriatal
degeneration in these genetic forms of parkinsonism, seems to be similar to
idiopathic PD by SPECT or PET imaging.
3. TREATMENT OF PD
Treatment of PD consists of medication, exercise, and in some rare cases
surgery. So far, drug treatment of PD is symptomatic dopamine (DA)
replacement therapy. Levodopa (L-dopa), an immediate precursor of DA, has
been used to relieve PD symptoms since the late 1960’s 105 and it is still the
most important and most efficient drug in PD. Long-term treatment of L-dopa
results in the development of motor complications after five years of L-dopa
treatment in half of the patients or more 106. The effect of L-dopa becomes
shorter (wearing off) and dyskinesias occur usually when the plasma levels of
L-dopa are highest (peak-dose dyskinesia). Co-administration of L-dopa with
peripheral dopa-decarboxylase inhibitors (benseratzide or carbidopa)
diminishes peripheral formation of DA and peripheral side effects of L-dopa,
and increases the amount of L-dopa entering the brain where it is converted to
DA in the dopaminergic neurons. COMT inhibitors (entacapone, tolcapone) also
increase L-dopa availability in the striatum by inhibiting its COMT-dependent
conversion into inactive metabolites. COMT inhibitors are only used with L-
dopa and may allow reduction of L-dopa dose and prolong the L-dopa dosing
interval 107, 108.
Dopamine agonists mimic the actions of DA in the striatum and stimulate DA
receptors directly.  DA agonists are effective as monotherapy in early PD, and
with L-dopa in more advanced disease 109. However, agonists are not as
effective as L-dopa, especially in late-stage disease, and L-dopa is eventually
needed in most patients. 110 Early use of DA agonists as monotherapy or as L-
dopa add-on may delay motor complications in comparison to L-dopa
monotherapy 106, 111.
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MAO-B inhibitors (selegiline and rasagiline) reduce catabolism of striatal DA
and thereby increase DA levels in SN and basal ganglia 112. Selegiline has
antiparkinsonian efficacy as monotherapy in early PD and may delay the need
for L-dopa 113, 114, but its effect is only mild to modest. Selegiline and rasagiline
can extend the effect of L-dopa and improve symptoms in L-dopa-treated
patients with fluctuations 115, 116. Anticholinergics were the first and only drugs
with therapeutic efficacy for PD from the late 1940’s until late 1960’s.
Anticholinergics may be useful in tremor-predominant PD but their efficacy is
not comparable to L-dopa 110 and cognitive adverse effects limit their use
particularly in older patients 117.
Antiparkinsonian properties of amantadine, originally introduced as treatment
and prophylaxis of influenza A, were reported late in the 1960’s 118.
Amantadine acts as an NMDA antagonist, can increase dopamine secretion and
inhibit its re-uptake, and has some anticholinergic effects 119, 120.
Amantadine’s therapeutic effect is only mild 121. It may relieve dyskinesias in
L-dopa-treated fluctuating patients 122.
Deep brain stimulation (DBS) of the subthalamic nucleus, globus pallidus, or
thalamus may be used for some cases with severe fluctuations or intolerance
to drug therapy and can relieve a wide range of symptoms 123. Thalamic DBS
may be an option for patients with severe tremor 124.
Stem cell transplantation has only been in experimental use.  Uncontrolled
open-label trials of fetal dopaminergic grafts on advanced PD patients have
reported clinically meaningful improvement 125-127, but a placebo-controlled
double-blind trial found no significant overall treatment effect, and a major
problem has been the appearance of persisting dyskinesia in most patients
with transplants 128. Post-mortem studies have revealed another problem with
this method: the disease process seems to spread to the transplant 129, 130.
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Coenzyme Q10 (ubiquinone) seemed to delay functional decline of PD patients
in a small preliminary study 131 but no established neuroprotective therapy is
currently available for PD.
4. ETIOLOGY OF PD
4.1 Environmental risk factors
In the early 80’s it was discovered that several people developed parkinsonism
after injections of drugs contaminated with 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) 132, 133. This discovery suggested that environmental
toxins may be related to risk of PD.
Smoking cigarettes and drinking coffee have been consistently shown to
protect from PD 134-136. Fairly consistent evidence suggests association
between pesticide exposure and PD risk 137, 138. Increased PD risk has also
been connected to rural living and well water use 139 as well as welding and
exposure to heavy metals such as lead, manganese, iron, and copper 137, the
evidence for these associations still being inconclusive 5, 140. Repeated head
trauma may increase risk of PD 141.
Results considering nutrients in PD risk are incoherent. Polyunsaturated fatty
acids have been suggested to decrease and consumption of dairy products
increase PD risk 5. Whether cholesterol has an effect on PD risk, and to which
direction, needs further studies: High cholesterol levels have been found to
increase susceptibility to PD in a recent Finnish study 142, whereas low
cholesterol, especially low LDL, in another study 143.
26
4.2 Genetic factors
4.2.1   Genetic epidemiology
Most PD cases occur sporadically, and PD was long thought to be of purely
environmental origin. In recent years increasing evidence has been found for
the significance of a genetic component in the etiology of PD based on
pedigree analyses and twin studies. Earlier twin studies relied on clinical
criteria and found low concordance levels, which lead to the interpretation that
genes have little or no effect in PD susceptibility 144, 145. However, a large study
of male twins reported a significant effect of genetic factors in patients with
age at PD onset less than 50 years 146.  An Icelandic genealogical study found
markedly increased risk of PD in relatives of patients with late onset PD, and
thus provided evidence for a contribution of genes also in the more common
sporadic late-onset form of this disease 4.  Another twin study, in which F-
DOPA PET was used to detect subclinical PD, found significantly higher
concordance for subclinical PD in monozygotic compared to dizygotic twins
(55% vs. 18%), which further confirms the role of genes in PD 147. Since late
1990’s, rare monogenic forms of PD have been recognized 148. Only in late
1990s a consensus emerged that idiopathic sporadic PD seems to result from
interplay of genetic and environmental factors.
4.2.2   Genes or loci of familial PD
To date, eight genes and five genetic loci for familial Mendelian inherited PD
are known (OMIM 168600). These 13 PARK loci are summarized in table 3.
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Table 3. The genetic loci of familial parkinsonism. (OMIM #168600 )
LOCUS MAP
POSITION
GENE INHERITANCE ONSET POPULATION CLINICAL AND PATHOLOGICAL FEATURES Ref.
PARK1 4q21 Alphasynuclein
(SNCA)
AD 40s Italian, Greek, German LB+ nigral degeneration,
typical and atypical parkinsonism, dementia
149
PARK2 6q25.2-q27 Parkin AR 20-40 Japanese, Spanish,
Italian, Brazilian
Early (even juvenile) onset
Classic symptoms of parkinsonism+ foot dystonia, marked sleep
benefit, hyperreflexia in some
Different pathology:no LB’s
150
PARK3 2p13 unknown AD 60s European LB+ nigral degeneration, some have plaques and tangles 151
PARK4 4q21 SNCA, duplication or
triplication
AD 30s English-German
Swedish-American
Early age at onset, early weight loss, rapidly progressive l-dopa-
responsive parkinsonism, dementia,
LB+ degeneration
152
PARK5 4p14 UCHL1 AD 50 German Clinically typical parkinsonism with response to l-dopa.
Pathology not reported
153
PARK6 1p36 PINK1 AR 30-40 Asian, Italian Most patients have features similar to those of idiopathic PD, a
subset demonstrate features similar to those of PARK2. Slow
progression.
Pathology not reported
154
PARK7 1p36 DJ-1 AR 30-40 Dutch, Italian Clinically typical + psychiatric disturbances.
Pathology not reported
155
PARK8 12q12 LRRK2, dardarin AD 60 Japanese,
Basque,English,
Ashkenazi Jewish
German Canadian
Most common known cause of AD parkinsonism. Clinically
mostly typical. Pathology variable, LB’s in most, tau in some
156
PARK 9 1p36 ATP13A2 AR 20-40 South-American,
Jordanian
Kufor-Rakeb syndrome, early onset parkinsonism with dementia,
supranuclear upgaze paresis, pallidopyramidal degeneration
157
PARK10 1p32 unknown AD? 60 Icelandic Typical, late-onset
Pathology not reported
158
PARK11 2q36-q37 unknown AD? Late? North American Clinically typical, pathology not reported 159
PARK12 Xq21-25 unknown X-linked Late? North American Clinically typical, pathology not reported 160
PARK13 2p12 HTRA2 AD? 49-77 German Typical parkinsonism, response to l-dopa. Pathology not
published
161
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4.2.3 Genes in sporadic PD
4.2.3.1  Approaches in genetic studies of sporadic PD
In Mendelian traits a single mutated disease gene causes the disease in
subjects carrying one (dominant) or two (recessive) copies.
In multifactorial diseases, such as PD, the particular disease gene does not
directly cause the disease but confers susceptibility to it. Under particular
environmental conditions subjects with predisposing alleles may develop the
disease. A straightforward common disease-common variant (CD-CV)
hypothesis suggests there may exist common variants that contribute to
genetic risk for common diseases 162, 163. A prototypic example supporting this
still debatable hypothesis is the contribution of APOE ?4 allele in Alzheimer’s
disease and cardiovascular disorders 164, 165.
Genetic association studies try to identify disease genes by finding association
between a genetic marker and the disease phenotype. A genetic marker is
associated with the disease if the frequency of the marker allele or genotype
differs significantly between affected and unaffected individuals. Association
studies are based on linkage disequilibrium (LD) 166-168. This means indirect
detection of the disease allele with an adjacent genetic marker (“guilt by
neighbourhood”). Hence, association between the disease and the marker
allele does not imply causal effect of this marker allele but reflects its LD with
the disease allele.
The magnitude of LD between the marker allele and disease allele is
determined by at least five factors 167. 1.Recombination frequency between the
two alleles, which roughly correlates with the distance of the alleles. 2. Age of
the mutation creating the younger allele. The older the mutation event
creating the younger allele, the more time there has been for recombination to
equilibriate the association. 3.Single origin vs. multiple origins of the alleles. If
both alleles have been created only once, LD is stronger as compared to the
situation in which one or both alleles have been created multiple times by
mutation. 4. The frequency of the allele adjacent to the younger new mutation.
If a new mutation occurs in the neighbourhood of a high frequency allele, LD is
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lower than when it is paired with a rare allele. A high frequency allele is a less
specific marker of a new mutation than a rare allele occurring in combination
with the new mutation. 5.Characteristics of the study population. Features that
tend to increase LD are recent founding of the population, low number of
founders, isolation of the population, bottlenecks during the population history
(famines, wars), genetic drift 169. Non-random mating and inbreeding also tend
to increase LD of the population.
M CA G
WT TG T
GENERATIONS
M CA G
M TA T
M CG G
M CA T
M CA G
M CA G
WT TG T
WT TG G
WT TG G
WT TG G
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WT TG T
WT CG G
M TA T
M CA T
WT TG T
Figure 1. The idea of
association studies
utilizing LD. A mutation
(M) occurs on an ancient
chromosome surrounded by
3 SNP’s with alleles A, C,
and G, whereas in wild type
(WT) the alleles of the
corresponding SNP’s are G,
T, and T. Through
generations recombinations
happen, but statistical
connection of the closest
alleles and the mutation
remains detectable. Here 7/8
(88%) of A alleles on site 1,
6/7 (86%) of C alleles in
site 3 mark the mutation
indicating LD.  Site 4 is no
more in apparent LD with
the mutation after multiple
generations: G occurs
equally frequently (50%) in
combination with the
mutation and the wild-type
allele.
Site 1 Site 2 Site 3 Site 4
The physical dimension of LD varies in different genomic regions and between
populations. A whole-genome average estimate of 60 kb for practically
meaningful LD (|D’|>0.5) for disease association studies has been suggested
170.
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Genetic association studies have traditionally focused on candidate genes
based on hypotheses on the disease pathogenesis. Candidate gene studies
have been widely used to identify susceptibility genes in many multifactorial
diseases, including PD.  Genome-wide association (GWA) studies use high-
throughput genotyping technology to assess up to hundreds of thousands of
SNP’s across the genome and relate them to disease phenotype. Generally the
associations found by GWA may be considered preliminary and need to be
confirmed by other studies. When hundreds of thousands markers are tested
the number of comparisons is so high that p-values of 10-5 are expected to
occur several times by chance alone. Replication is here the proof rather than a
single low p-value.
4.2.3.2 Problems in interpreting the data
Association of PD with more than 200 candidate genes has been studied
(Appendix). Association of some genes and PD has been found repeatedly and
some are clearly negative, but the role of many of these genes is still
inconclusive. For instance, what to think of the role of a gene in PD
susceptibility if there are three studies with positive  (association with PD) and
six with negative results? When interpreting the published data, one has to be
aware of the many potential sources of error in genetic association studies.
? Positive findings tend to get published more readily than negative ones
(publication bias).
? Population substructures affect case-control association studies as cases
and controls may derive from distinct subpopulations (population
stratification bias). Family-based association studies have been
developed to overcome this problem 171, but these are not easily
applicable to PD due to the high age of the patients (parents often
deceased).
? The genetic association may be restricted to certain population(s) only
(genetic heterogeneity).
? The genetic methods may not be comparable: Some studies have
directly searched for mutations and some have tested association of
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common variation indirectly, via linkage disequilibrium, with PD.
Moreover, in some studies only one or few polymorphisms per gene have
been studied, which may be too little to for the evaluation of a gene’s
role in disease susceptibility. More comprehensive analyses with
numerous markers per gene and haplotype analyses possess higher
genomic information content. Analysis of a polymorphism that has
functional consequence on protein function is usually more “informative”
than analysis of a non-functional marker.
? Different size patient materials have been used, some of which possibly
have insufficient power.
? Patient selection criteria may not be identical (phenotypic
heterogeneity).
Meta-analysis is one means of reducing the noise from conflicting reports.
However, albeit helpful in interpreting the exuberant data, meta-analyses also
face some problems: publication bias tends to magnify positive findings. On
the other hand, the use of large combined material in the meta-analysis may
lead to loss of population-specific associations. Another problem may be that
search engines may omit some studies that have not used the most commonly
searched words and these studies might thus be left out of meta-analyses.
4.2.3.3   Expansion of data
A PubMed search in April 2008 with key words “sporadic”, “Parkinson’s
disease”, and “gene”, limited to humans and English language, yielded 432
results. Limited to publication years 1990-1994, this search yielded only seven
results. A search limited to the next five years (1995-1999) found 74 results,
162 in the five years thereafter, and 189 in the last four years. A closer look at
these search results revealed that 3 out of 7, 25 out of 74, 64 out of 162, and
104 out of 189 were genetic candidate gene association studies on sporadic
PD. Surprisingly many other published studies, not found in the PubMed search
although published in well-known peer-reviewed journals, were found via a
database for Parkinson’s disease genetic association studies in
www.PDGene.org by Massachusetts General Hospital / Harvard Medical School
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and Michael J. Fox Foundation. Thus, the search results by PubMed are far
from inclusive, but do indicate the rapid growth of articles in this field.
      N
  (publications)
1990-94 1995-99 2000-04 2005-08
(5 yrs) (5 yrs) (5 yrs) (3.27 yrs)
n=7 n=74 n=162 n=189
Figure 2. Growth in the number of publications on the genetics of sporadic PD.
PubMed search of original articles in peer-reviewed journals using English
language (keywords “sporadic”, “Parkinson’s disease”, “gene”).
4.2.3.4  Selected candidate genes analyzed in sporadic PD
The genes of monogenic parkinsonism (table 3) are potentially interesting
candidate genes also in the etiology of sporadic PD due to the clinical and
neuropathological similarity of the diseases.  Of these genes, SNCA has shown
allelic association with sporadic PD in several studies 172-177 but the mutations
of monogenic PD or multiplications are rare in sporadic patients 178-183. LRRK2
mutations, the most common known cause of AD parkinsonism so far, are also
found in apparently sporadic PD patients in several populations. Most common
of the LRRK2 mutations is a low penetrance mutation G2019S, which is most
common in North African Arabs (as high as 41% in sporadic patients) and
Ashkenazi Jews (~29% familial and ~13% sporadic patients) 184, 185. It is also
present in relatively high frequency in Southern Europe such as Italy, Spain
and Portugal (5-18% in familial and 1-6% in sporadic patients) 186-188 whereas
in Northern European patients (Scandinavian, Russian, Polish, British) it is
much less common (0-1.6% in sporadic patients) 189-193. The carriers of
G2019S share an ancestral haplotype 186 suggesting a common founder, which
explains the remarkable interpopulation variation in frequency.
100
200
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In addition, association of sporadic PD and genes involved in other
neurodegenerative disorders, dopaminergic transmission or dopamine
metabolism, xenobiotic metabolism, mitochondria, and immune response has
been extensively studied. Several associations have been reported but few
associations have been confirmed in subsequent studies. Of the 265 genes
(Appendix) studied in association to PD susceptibility only the most interesting
ones are presented here and in table 4. Parkin, DJ-1, APOE, COMT and POLG
are discussed in more detail because they are included in the studies of this
thesis.
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Table 4. Interesting candidate genes studied in sporadic PD
Association or
mutation analyses
Gene
Mostly
positive
Conflicting
Comments Refs
Genes of monogenic PD
SNCA X Allelic association with non-coding
markers in many studies. Missense
or nonsense mutations and
multiplications rare
172, 174,
176, 177
LRRK2 X Low penetrance mutation G2019S in
0-41% of apparently sporadic
patients
185, 194-
198
DJ-1 X No association with sporadic PD 199, 200
Parkin X Mutations present in juvenile and
early onset patients. Possible
associations of coding SNP’s and
sporadic PD.
201-207
PINK1 X Heterozygous mutations, in some
reports, slightly enriched in
sporadic patients.
208-210
UCHL1 X Some studies have suggested S18Y
protective
211-213
Other genes involved in neurodegeneration
APOE X Reports of both ?2 and ? 4 in
increased PD risk. Associations with
PD dementia or onset age suggested
214-220
MAPT (tau) X OR 1.3-1.4 for the common H1
haplotype homozygocity
221
Glucocerebrosidase(GBA) X The gene of Gaucher’s disease, 222-224
POLG1 X Two small negative studies on
POLG1 in sporadic PD
225, 226
Genes involved in DA metabolism or dopaminergic transmission
COMT X Val/Met polymorphisms effect to
PD medication also studied (no
effect)
227-231
DAT X 232-235
Monoamine oxidase B (MAO-
B)
X 236-239
Genes involved in the metabolism of toxins
CYP2D6 X Poor metabolizer genotype
suggested to increase PD risk in few
studies, possible pesticide
interaction
240-243
Alcohol dehydrogenase 1c
(ADH1c)
X X Only one study (positive) 244
N-acetyltransferase (NAT2) X Slow acetylator genotype suspected 245-248
Glutathione-s-transferases
(e.g.GSTP1, GSTPM1)
X Possible gene interaction with herbi-
/pesticides
249-252
Paraoxonase 1(PON1) X 253, 254
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4.2.3.4.1  Parkin
Parkin protein functions in the cellular ubiquitination/protein degradation
pathway as an E3 ubiquitin ligase. Loss-of-function mutations of parkin are
suggested to lead to accumulation of non-ubiquitinated substrates, detrimental
to the dopaminergic neurons. Patients with mutations in the parkin gene
generally do not show ubiquitin-positive Lewy bodies, which is probably
explained by the failure of ubiquitination 255.
Parkin gene is located on chr 6q25 with 12 exons spanning 1.3Mb of genomic
DNA. Parkin mutations were first described in Japanese families with juvenile-
onset autosomal recessive parkinsonism 150. Since then, PD-associated parkin-
mutations have been described in all exons, and include point mutations, small
insertions/deletions and larger deletions, and exon duplications and
triplications 256. Parkin mutations have turned out to be a common cause of
early-onset parkinsonism, especially in patients with evidence for recessive
inheritance 257, 258. Parkin mutations are also responsible for majority of
sporadic cases with very early (<20y) onset and are common (25%) in
patients with onset at 20-35 years of age 258, 259. Some studies have found
heterozygous parkin mutations in early- and late-onset patients but not in
controls, suggesting also heterozygous parkin mutations may increase
susceptibility to PD 260, 261. However, heterozygous parkin point mutations were
as common in cases as in controls in another study 262. Therefore, the role of
heterozygous parkin mutations remains a matter of debate. Some coding
polymorphisms of parkin have been suggested to associate with sporadic PD in
Japanese as well as European populations 201, 203, 207.
Early onset, diurnal fluctuations of symptoms, benefit from sleep, foot
dystonia, hyperreflexia, and good response to l-dopa but early susceptibility to
levodopa-induced dyskinesias are typical features of patients with parkin
mutations. Lewy bodies are typically not found 259, 263. Nevertheless, the
phenotypical spectrum may be broader since a phenotype indistinguishable
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from typical idiopathic PD has been reported in a pedigree from South Tyrol
with compound heterozygous parkin deletions 264.
4.2.3.4.2  DJ-1
DJ-1 protein has been ascribed various functions but the most relevant in
terms of the pathogenesis of PD is its potential role in oxidative stress
response, either as redox sensor or antioxidant protein, and relation to
mitochondrial function. In the presence of oxidative stress, wildtype DJ-1
translocates to outer mitochondrial membrane and is supposed to be involved
in neuroprotection 265, 266. DJ-1 expression in the brain is ubiquitous, with
higher levels of the transcript in the caudate nucleus, thalamus, substantia
nigra, and hippocampus 155.
DJ-1 gene on chr 1p36 contains 8 exons spanning 24 kb. The first two exons
are non-coding and alternatively spliced in the mRNA. DJ-1 mutations include
missense, truncating, splice site mutations and large deletions, and are the
rarest among the known genetic causes of autosomal recessive parkinsonism,
being present in about 1-2% of early-onset cases 102, 155, 199, 256, 267. DJ-1
mutations contribute rarely to the development of sporadic PD 199.
4.2.3.4.3  Apolipoprotein E (APOE)
APOE (Chr 19q13) gene has three common alleles designated ?2, ?3 and ?4
determined by amino acid substitutions arginine or cysteine in positions 112
and 158 of the APOE protein. ?4 allele is a risk factor for Alzheimer’s disease
164, 268 whereas ?2 is protective and ?3 has been considered “neutral”. APOE
?2/3/4 polymorphism has also been shown to affect prognosis after brain
haemorrhage or trauma 269, 270. Also ?3 haplotypes have been reported to be
different and affect risk of neuropathologically verified Alzheimer’s disease and
brain beta-amyloid deposition 271.
Reports of APOE ? polymorphism in PD susceptibility have been conflicting,
mostly negative. Both ?4 and ?2 have been suggested to increase risk of PD
272-275 or associate with earlier age at onset 274, 276, 277. Some studies have
37
indicated that ?4 might increase the risk of PD dementia or cortical Lewy body
pathology 215, 278, 279.
4.2.3.4.4  Catechol-o-methyltransferase COMT
COMT is an intracellular enzyme present in soluble (s-COMT) and membrane-
bound (MB-COMT) isoforms which function in elimination of biologically active
or toxic catechols and some hydroxylated metabolites. COMT also acts as a
detoxicating barrier between the blood and other tissues (e.g. in the intestinal
mucosa and the brain) shielding against the detrimental effects of xenobiotics
108.
COMT gene is located on chromosome 22q. Methionine instead of valine at
amino acid residue 158  (or 108 of S-COMT) results in thermolability and lower
activity of the enzyme. Thus, this Val158Met polymorphism encoded by a G to
A polymorphism in the corresponding codon in exon 4 of COMT gene
determines the high and low activity forms of COMT 280. Association of COMT
Val158Met polymorphism has been extensively studied with various psychiatric
conditions with inconclusive results 281. Because of its role in dopamine
metabolism and detoxication, COMT is a tempting candidate gene in PD. The
role of COMT Val158Met polymorphism in the susceptibility to PD is
controversial: both low 227, 229 and high 231, 282 activity alleles have been
suggested to increase PD risk.
4.2.3.5 Genome-wide association (GWA) studies on sporadic PD
So far four GWA studies on sporadic PD have been published. In addition, two
GWA meta-analyses have been made 283, 284. An American study by
Maraganore et al (2005) found 13 SNP’s potentially important for determining
the risk of PD 285, but subsequent case-control studies were not able to confirm
any of these 13 associations 286, 287. Foltynie et al reported association on chr
1p31 near PARK10 locus 288. A GWA study in Dutch patients suggested
association with chromosomes 9q and 14q and also suggested weak signal
near MAPT and SNCA regions 289. Fung et al studied in US patients 408 000
SNP’s, none of which remained significant after correction for multiple testing
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290. The meta-analysis by Evangelou (2007) did not find any significant
associations either 283. Fung and Maraganore have released their GWA data
publicly available for future mining and augmentation.
Because of a large number (up to hundreds of thousands) of SNP’s tested in a
GWA study the risk of false positive findings is considerable. On the other
hand, the commonly used Bonferroni correction for multiple testing may be too
conservative and lead to false negative interpretations in GWA studies. GWA
approach largely relies on the common disease - common variant hypothesis.
Many important disease-causing or disease-predisposing variants may be rare
and therefore not as readily detected by GWA approach. In addition, lack of
information on gene function, insensitivity to structural variants, requirement
for large samples, possible genotyping and case and controls selection biases,
and high price are limitations of GWA studies 291. Even though the associations
found in GWA studies need to be confirmed by several other studies and large
samples, GWA studies are effective means to find new candidate genes and
generate new hypotheses.
4.3 Mitochondria and PD
The primary function of mitochondria is the production of cellular energy in the
form of ATP by oxidative phosphorylation. They also have roles in controlling
and mediating apoptosis, heme and steroid synthesis, free radical scavenging,
calcium homeostasis and heat production 292. Mitochondria are intracellular
double-membrane organelles. The five complexes of the mitochondrial
respiratory chain are located on the inner membrane. Mitochondria have their
own maternally inherited genome. Mitochondrial DNA (mtDNA) is a circular
double-stranded 16.5 kb DNA-molecule. However, majority of the
mitochondrial proteins are encoded by nuclear DNA, synthesized in the cytosol
and imported into mitochondria 293.
Classical experiments with MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) have suggested a role for respiratory chain defects in PD,
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since MPTP exposure has resulted in dopaminergic neuron loss and
parkinsonism through inhibition of mitochondrial respiratory chain complex I
294, 295. Mitochondrial complex I deficiency in substantia nigra and platelets of
PD patients has been reported 296, 297.  Many gene products of familial PD are
implicated in mitochondrial function: PINK1 (PARK6), HTRA2/Omi (PARK13)
and DJ-1 (PARK7) localize to mitochondria 298 and loss-of function mutations of
parkin (PARK2) cause mitochondrial dysfunction and oxidative damage 299-301.
MtDNA deletions accumulate in the SN neurons along with aging, but mtDNA
deletions are more abundant in the nigral neurons of PD patients than in age-
matched controls 302, 303. Certain specific mtDNA mutations or polymorphisms
have been reported to associate with PD but this has not been consistently
replicated 304-307. Also specific mitochondrial haplotypes have been suggested
to influence PD expression 308-310.
4.3.1 Mitochondrial DNA polymerase gamma (POLG)
POLG is responsible for the replication and repair of mtDNA. The catalytic ?-
subunit of POLG is encoded by a nuclear gene, POLG1, on chromosome 15q25.
POLG consists of a N-terminal 5’-3’ exonuclease domain, C-terminal
polymerase domain and a ‘spacer’ region. Spacer region is involved in DNA-
binding and in mediating the interaction with the accessory ?-subunit, a
processivity factor, encoded by a separate gene 311. The consequence of
POLG1 defects is the accumulation of secondary mutations and deletions of
mtDNA, which leads to progressive respiratory chain deficiency. In 2001
POLG1 mutations were first connected to autosomal dominant progressive
external ophtalmoplegia (PEO) 312. Since then, a myriad of POLG1 mutations
with various clinical manifestations, e.g. Alper’s syndrome (retardation,
epilepsy and liver failure in infants), ataxia, neuropathy, myopathy, epilepsy,
hepatopathy, valproate sensitivity, infertility, premature ovarian failure, and
deafness, have been described 313-319. Interestingly, also parkinsonism has
been reported as a part of these POLG –associated syndromes 316, 317, 320-322.
The polyglutamine tract of POLG1 is discussed later.
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4.4 Interaction of genes and environment
Complex diseases such as PD are widely believed to result from interplay of
genetic predisposition and environmental risk factors. The individual genetic
effects may be small and difficult to detect consistently 323. It has been
proposed that inconsistency in genetic associations might be due to
unrecognized interactions with environmental factors or other genes 324.
Therefore focusing on gene-environment or gene-gene interactions is of
growing interest.
Coffee consumption and smoking have consistently been found to be protective
against PD. In a large meta-analysis a pooled relative risk of 0.59 was
calculated for ever-smokers vs. never-smokers, and 0.69 for coffee drinkers vs
non-coffee drinkers 135. Recently McCullough et al (2008) studied the
interactions of smoking and drinking coffee with genetic factors such as APOE
?2/3/4, MAPT H1/H2, and SNCA promoter repeat Rep1 alleles. In their material
APOE ?2 was associated with nearly two-fold PD risk in those who did not drink
coffee, but this predisposing effect of ?2 waned with increasing coffee
consumption. They also suggested interaction between SNCA Rep1 allele
length and smoking 324. Clearly these findings should be considered
hypotheses that demand verification, but they serve as examples of the
possible gene-environment interactions. There is previous evidence for a
putative interaction of APOE with smoking and alcohol consumption in the risk
of cognitive decline 325. There are, however, no precedents of the interaction
between SNCA and smoking.
A gene-gene synergistic interaction in PD risk has been suggested between the
MAPT (tau) H1 haplotype and SNCA (SNP rs356219 from the 3' region of
SNCA). By studying 650 PD patients from the UK, Goris et al (2007) found that
carrying a risk genotype at either of these loci modestly increased the risk for
development of PD. Odds ratios (OR) were 1.34 (p=0.002) and 1.45
(p=0.003) for the MAPT H1/H1 and SNCA rs356219 G/G genotypes. The
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combination of risk genotypes at both loci approximately doubled the risk (OR
2.14, p=0.000003) 221. There is biochemical evidence for an interaction of the
protein products tau and ?-synuclein. It has been shown they can seed each
other’s aggregation at low protein concentrations 326. There is increasing
clinical and neuropathological evidence suggesting that synucleinopathies and
tauopathies are linked 327, 328.
Possible interaction of herbicides and genes encoding detoxicating enzymes
has been proposed. Glutathione transferases (GST) are a family of inducible
phase II enzymes that metabolize xenobiotics, including pesticides. GSTP1
haplotypes were reported to associate with an increased PD risk in subjects
exposed to pesticides 252. Another study suggested that herbicide exposure
modifies the effect of GSTP1 haplotypes on the age of PD onset 249. Also
GSTM1 null subjects heavily exposed to solvents may be at increased PD risk
251.  The debrisoquine hydroxylase (CYP2D6) metabolizes several xenobiotics,
including organophosphate pesticides and MPTP. CYP2D6 activity is genetically
determined. Being a “poor metabolizer” is a recessive trait. 5-10% of white
population is poor metabolizers with undetectable CYP2D6 activity. In a French
study, among subjects exposed to pesticides, the risk of PD was increased
twofold among CYP2D6 poor metabolizers in comparison with non-poor
metabolizers. Pesticides had a modest predisposing effect in subjects who are
not poor metabolizers. On the other hand, poor metabolizers were not in
increased PD risk in the absence of pesticide exposure 242. These examples fit
into the hypothesis where a genetic predisposition (genetic variation/defect in
a detoxicating enzyme) exists resulting in toxic injury to the neurons and the
development of PD.
4.5 Hypotheses on the pathogenesis of PD
Although the pathogenesis of sporadic PD is still a mystery, discovery of the
genes of familial PD have highlighted some pathways involved in nigral
degeneration, including altered or increased ?-synuclein (SNCA), impaired
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protein degradation and protein aggregation, mitochondrial dysfunction, and
oxidative stress.  Also excitotoxicity and inflammation may contribute to the
pathogenesis 329.
SN has a high propensity for oxidative stress and is deficient in protective
mechanisms 330. The susceptibility of dopamine (DA) and its metabolites to
produce reactive oxygen species (ROS) might explain the vulnerability of the
SN neurons 331. In addition, SN is rich in iron and copper, and the oxidation-
reduction cycle of iron can produce free radicals. Mitochondrial dysfunction,
which leads to uncoupling of redox reactions and production of ROS, has also
been implicated in PD 298 and is discussed above in its own chapter. Some
evidence from post-mortem studies suggests that the SN might be short of
antioxidant molecules, e.g. glutathione 332. Of the familial PD loci, PINK-1 and
DJ-1 seem to be involved in the responses to oxidative stress, and their
mutations might therefore lead to defective oxidative stress tolerance 333.
Another explanation for SN involvement could be the dopamine transporters
(DAT) on dopaminergic cells 334. MPTP and 6-hydroxydopamine that produce
experimental parkinsonism enter the dopaminergic neurons via DATs, and in
transgenic mice even modest differences in the expression of DAT influence the
dopaminergic neuronal damage caused by experimental toxins 335, 336. Mice
that express no DAT are resistant to MPTP 337.  DAT might also be the route of
environmental toxins to the SN.
Considerable evidence, such as mutations or multiplications of SNCA in familial
PD and allelic association with sporadic PD, and the role as major component
of LB’s and Lewy neurites, suggest involvement of SNCA in the pathogenesis of
PD. This is supported by the results of Dauer et al: SNCA null mice were shown
to be resistant to neurotoxicity of MPTP 338. Increased localization of SNCA to
the nucleus, by mutations in or increased expression of SNCA, might be toxic
to neurons through decreased histone acetylation, possibly leading to
aberrations in transcriptional control, and ultimately to cell death 339.
Phosphorylation of SNCA may affect its neurotoxicity, possibly by causing
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increased nuclear localization of SNCA 340. Mutations in or over-expression of
SNCA may lead to abnormal fibril formation and aggregation of SNCA 152, 341.
Adult-onset loss of dopaminergic neurons, intraneuronal SNCA-containing
inclusions, and a movement disorder were seen in a Drosophila model of
mutant SNCA 342. SNCA aggregation may also be promoted by free radicals,
and dopamine metabolites 343, 344. It has been suggested that actually smaller
oligomers of SNCA, protofibrils or Lewy neurites may be the culprits in
neuronal degeneration whereas LB’s might be relatively inert dumping grounds
344, analogous to Alzheimer’s disease 345.
LRRK2 and PINK1 both encode protein kinases, and might be involved in
phosphorylation of proteins that accumulate. Pathogenic mutations seem to
increase the kinase activity of LRRK2 in vitro, which may suggest a toxic gain-
of-function mechanism 346, 347. Their substrates are not known, but their
indirect targets have been suggested to include SNCA and tau, phosphorylated
species of which have been associated with toxicity and accumulation as LB’s
or Lewy neurites and neurofibrillary tangles, respectively 348.
Proteolytic stress may underlie cell death in PD. Normally abnormal, damaged,
misfolded or otherwise unwanted proteins are degraded by the ubiquitin-
proteasome (UPS) system 349. Tagging these proteins with ubiquitin signals
their transport to the proteasome for degradation. If production of misfolded
protein exceeds the degradation capacity of the UPS, proteolytic stress arises
and may lead to accumulation of these proteins and impairment of cellular
functions. Of the gene products of familial PD, SNCA, UCHL1 and parkin can be
theoretically linked to proteolytic stress. Parkin (a ubiquitin E3 ligase) and
UCHL1 (ubiquitin carboxyterminal hydrolase) operate in the UPS. Mutations in
them may lead to impairment in UPS and accumulation of proteins, including
SNCA 329. The ability of parkin to ubiquitinate protein might also be impaired
by S-nitrosylation resulting from exitotoxic damage 350. Proteasomal
impairment has been observed in post-mortem studies on sporadic PD 351. It is
possible that proteasomal dysfunction is not a primary phenomen in PD but
secondary to oxidative stress or mitochondrial dysfunction 329.
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Autophagy-lysosome pathway (ALP) is another means to degrade cytosolic and
misfolded proteins, and impairment of ALP may also lead to accumulation and
aggregation of proteins, resulting in cellular toxicity. ALP is considered the
default pathway when an aggregate-prone substrate cannot be degraded by
the proteasome. Three forms of ALP are macroautophagy, chaperone-mediated
autophagy (CMA) and microautophagy 352. Wild-type SNCA can be degraded
both by the UPS and by ALP, but mutated SNCA cannot be degraded by the
CMA : although it binds to the lysosomal membrane with high affinity, it does
not translocate into the lysosome. Mutant SNCA, by its high-affinity binding,
also seems to block uptake and degradation of other substrates by the
lysosome, thus causing a more general CMA blockage 352.  SNCA mutations are
rare but more common are posttranslational modifications of SNCA, by e.g.
products of dopamine metabolism, which may impair degradation of SNCA by
CMA 353. Mutations in ATP13A2 (PARK9), a lysosomal ATPase, lead to a failure
of autophagy and aggregation of SNCA, further supporting the role of ALP
dysfunction in neurodegeneration 354.
Even though there is evidence supporting all these theories, the pathogenesis
and preferential neuronal vulnerability in PD remain unknown. Hypotheses on
PD pathogenesis are summarized in Figure 3.
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Figure 3. Hypotheses on the pathways and their connections in PD pathogenesis
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AIMS OF THE STUDY
The pathogenesis of PD is still largely unknown, and PD lacks neuroprotective
therapy. Knowledge on the pathogenesis would help development of
neuroprotective and even preventive treatments. Finding susceptibility genes
of PD helps to elucidate the pathogenesis.
The specific aims of this study were:
o To assess the accuracy and usefulness of 123I-?-CIT SPECT in PD
diagnosis in routine clinical practice (Study I)
o To study the association of PD and APOE ?2/3/4 polymorphism,
previously reported to affect susceptibility to or prognosis of various
neurological conditions, as well as to study the association of PD and
APOE promoter and enhancer polymorphisms, and APOE ?3 haplotypes,
the last three not previously studied in PD (Study II)
o To study the association of COMT, involved in dopamine metabolism, and
PD (study II)
o To test association of parkin and DJ-1, loci of familial PD, and sporadic
PD (studies II, III)
o To study the role of POLG1 variants in patients with PD, as mitochondrial
dysfunction has been suggested in the pathogenesis of PD and
parkinsonism was reported in PEO families with POLG1 mutations
(studies IV and V)
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MATERIALS AND METHODS
1. THE 123I-?-CIT SPECT STUDY
1.1 123I-?-CIT SPECT patients
In the study I, we included all 185 consecutive patients of the outpatient clinic
of the Department of Neurology, Helsinki University Central Hospital, who
underwent 123I-?-CIT SPECT based on clinical history and/or neurological
examination from 1996 to spring 1999. All had also MRI and/or CT. The most
likely clinical diagnosis was made based on standard clinical criteria, clinical
follow-up of at least 2-4 years after SPECT imaging, and MRI and/or CT
findings. Hoehn-Yahr and Schwab-England scales were used to assess the
disease stage of PD patients.
Of the 185 subjects (83 women/102 men) scanned with 123I-?-CIT SPECT, 92
patients had PD and 16 had essential tremor (ET). 15 patients with vascular
parkinsonism (VP) had either a focal vascular lesion in the basal ganglia area,
general leukoaraiosis or both, resistance to antiparkinsonian medication, and a
clinical picture typical to VP. 8 patients with MSA and 4 with PSP were together
grouped as a P+ group (N=12) in the statistical analysis. Of the 12 patients
with drug-induced parkinsonism, neuroleptics were regarded causative in
eleven and lithium in one. 5 patients had probable DLB, and 5 cervical or other
type of focal dystonia. 20 patients had fears or complaints suggestive of an
extrapyramidal disease, but had no unequivocal signs on neurological
examination and MRI was normal. In addition, clinical follow-up did not confirm
striatal dysfunction and the symptoms resolved during follow-up. Eleven of
them were diagnosed as having psychogenic parkinsonism. Nine similar
patients were not evaluated by a psychiatrist and therefore had no official
diagnosis of somatoform disorder, but we consider all twenty having
psychogenic parkinsonism. However, the numerical data of these subjects were
used only descriptively and not used for statistical analyses as they are not an
optimal control group. 8 patients (Alzheimer’s disease, cervical disc prolapse,
neurosyphilis, normal-pressure hydrocephalus, sequlae of radiculitis, post-
48
traumatic extrapyramidal symptoms, and 2 cases with ataxia NUD) did not fit
into any of the groups above and were therefore excluded from the statistical
analysis. Thus, the total N in the analyses is 177.
1.2 123I-?-CIT SPECT methods
SPECT scanning was performed 24 hours after an intravenous injection (185
MBq on average) of 123I-?-CIT. Before the tracer injection, thyroidal uptake
was blocked by 400 mg of oral potassiumperchlorate. A Picker Prism 3000XP
triple-head gamma camera with a low-energy, ultrahigh resolution (LEHR) fan
beam collimator (resolution 6.7 mm at 10cm distance) was used.  Data were
reconstructed using a ramp filter and 3D postfiltering with a low pass filter.
Chang attenuation correction was performed. 4.4 mm thick transaxial slices
were reformatted to the orbitomeatal line. Regions of interest (ROI) were
drawn on the striatum and separately on the caudate and putamen by using a
pre-defined ROI model, the shape and rotation of which was adjusted for each
measurement, and counts-per-pixel values were calculated for each ROI. A
ROI drawn on the cerebellum was the reference region with unspecific binding.
The striatal 123I-?-CIT uptake was expressed as the mean striatal counts
divided by cerebellar mean counts.
1.3 Statistical methods
The parametric analysis of variance (ANOVA/MANOVA) was used to analyse the
statistical significance of difference in means between the various diagnostic
groups. A p-value < 0.05 was considered significant. Tukey’s honest significant
test for unequal N was used to compare the mean uptake values in the patient
groups. Non-parametric Spearman rank correlation test was used to calculate
correlations.
The cut-off points for analyses of sensitivity and specificity were calculated
using a ROC-analysis with emphasis on high sensitivity. The sensitivity and
specificity of 123I-?-CIT was calculated in a 2 x 2 contingency table where
sensitivity was defined as the proportion of test positive cases out of all PD
49
cases, and specificity as the proportion of test negative cases out of all PD-
negative cases.
2. GENETIC ANALYSES
2.1 Patient inclusion criteria
We collected a case-control series  (II-IV) of idiopathic apparently sporadic PD
patients (N=147, 87 men/60 women) who had clinically typical PD from the
outpatient clinics of the Department of Neurology, Helsinki University Central
Hospital (96 patients) and Seinäjoki Central Hospital (51 patients). The PD
diagnoses were verified according to UK Brain Bank Criteria with a clinical
follow-up for at least 4 years or, alternatively, clinical follow-up for at least 2
years plus 123I-?-CIT-SPECT findings supporting idiopathic PD.  Demented and
atypical patients, as well as patients who reported first degree relatives with
parkinsonism were excluded.  Mean age of the patients was 67.2 years (range
38-88 years) at the time of sample collection.The patients’ neurologically
healthy spouses (N=137, 50 men/87 women) were recruited as controls.
In study IV, also two other control groups were used for the POLG CAG /polyQ
repeat analysis. Population controls (n=516) consisted of the previously
published Vantaa 85+ subjects (n=515, successful POLG poly-Q sequence
obtained in 447) 355 and healthy blood donors (N=69).
In study V, we used previously published publicly available PD and
neurologically normal Caucasian control samples from NINDS repository
(patient plates NDPT001, NDPT005, NDPT007, NDPT014, NDPT015, NDPT016,
NDPT017, NDPT018 and control plates NDPT002, NDPT022, NDPT023, and
NDPT024)
(http://ccr.coriell.org/Sections/Collections/NINDS/DNAPanels.aspx?PgId=19#)
. Of them, we excluded 24 patients who had other likely pathogenic mutation
(10 with parkin, 10 with LRRK2, and 4 with PINK1 mutation). A PSP patient,
erroneously in this sample collection, was excluded from our study.
Sequencing was successful in 652 patients (44 % females/ 56 % males), all of
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them Caucasians. The mean age of the PD patients was 65.3 (range 29-88)
years, and the mean age-at-onset (AAO) 56.9 (range 7-87) years.
Sequencing was successful in 292 control samples (51% females/49 % males).
The mean age of the controls was 68.2 (range 55-95) years.
Additional controls retrieved from two other sources, where POLG1 polyQ
(CAG-repeat) alleles had been defined by sequencing, were also used in
comparisons: mostly Caucasian controls (n= 605) from the doctoral thesis of
Anja Rovio (2006) http://acta.uta.fi/english/teos.phtml?10863  , p.60 , and
pooled Finnish controls from IV (n= 644, spouses and population controls).
2.2 DNA methods
DNA was extracted from blood leukocytes using standard phenol-chloroform
method.
II The genetic markers were amplified by PCR, digested with an appropriate
restriction enzyme and electrophoretically separated on agarose gels. Marker
alleles were visualized with ethidiumbromide by UV light.
For typing APOE ?2/3/4 polymorphism, previously published primers and
digestion enzyme HhaI were used 356. Additional SNP’s from APOE were also
genotyped: -219G/T (Th1) polymorphism in APOE promoter area (digestion
with BstNI), and +113G/C (IE1) in intron 1 (NlaIV).
PARKIN SNP genotypes Ser167Asn (AlwNI, exon 4), Arg366Trp (NciI, exon 10)
and Val380Leu (Bsp1286I, exon 10) were determined as previously described
203.
COMT Val158Met polymorphism was genotyped using previously published
primers and Nla III digestion 357. COMT SNP rs6270 was digested with BsmFI.
The primers used for amplification of rs6267 were 5’-
AGCATGCGGAGCCCGGGAAT*-3’ and 5’-CTGGAAATGGGGTGATAACAGC-3’.
A restriction site for BsmI was generated by a mutation (C->T) on the last
base (*) of the forward primer. Digestion of the G-allele yielded 170bp and
23bp fragments whereas T-allele had no restriction site for BsmI.
III PCR for DJ-1 exon 1 g. 168_185del was performed using primers
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5'-GAGGTAGACTCGGCCGGAC-3' and 5'-TTCTGGACGCTTCAGCGTTG-3' The
405 bp ins allele product and the 387 bp del allele were visualized with
ethidium bromide and UV on a 3% agarose gel.
IV, V The sequencing of the POLG1 exons was performed using previously
published intronic primers 312. The fragments were sequenced by automated
nucleotide sequencing with the BigDye terminator Ready Action Kit v 1.1 and a
3100 Genetic Analyzer automatic sequencer. The primers for the SNP’s
rs2238297 C/T and rs2302084 A/G were designed and restriction enzymes
searched using SciEd software. The PCR products were digested with the
restriction enzymes Tsp45I and MspI, respectively.
2.3 Statistical methods
In the genetic studies, ?2 or Fischer exact test were used to compare allele or
genotype frequencies between cases and controls. P< 0.05 was considered
significant.
Haplotype frequency estimation was carried out with the expectation-
maximization algorithm by using HAPLO 358 and SNPHAP software
http://www.gene.cimr.cam.ac.uk/clayton/software/snphap.txt  . HAPLO was
used to estimate haplotype frequencies in PD and control groups and to
calculate global p-values for association with PD whereas SNPHAP was used to
analyze the association of individual haplotypes with PD.
3. ETHICS
The study has been approved by the Ethics Committee of the Department of
Neurology, Helsinki University Central Hospital (65/1999) and by the Ethics
Committee for Ophthalmology, Otorhinolaryngology, Neurology and
Neurosurgery in the Hospital District of Helsinki and Uusimaa (439/E9/2000,
90/2001). The patients and controls gave their written informed consent.
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RESULTS AND DISCUSSION
1. 123I-?-CIT SPECT IN THE DIFFERENTIAL DIAGNOSIS OF PD (I)
Many studies had assessed 123I-?-CIT SPECT in PD patients vs. controls, or
other predefined case-control-setting with good results. This method’s ability
to differentiate between numerous diagnostic possibilities in clinical practise
had not been assessed in a single study.  We assessed the accuracy and
clinical usefulness of 123I-?-CIT SPECT in the differential diagnosis of 177
consecutive patients with signs or symptoms suggesting possible
extrapyramidal disease.
Figure 4. 123I-?-CIT images
of normal striata (up
left) and striata of a PD
patient (up right). Note
the interstriatal asymmetry
and putamen-predominant
reduction in ?-CIT uptake.
ROIs on the whole striatum,
putamen and caudate
nucleus have been drawn.
Anatomy of the striatum is
illustrated down.
Nucleus caudatus
Putamen
1.1 123I-?-CIT uptake in different movement disorders
The striatal ?-CIT uptake in all the patient groups is visualized in figure 5. The
means in all ROIS in all groups are presented in table 2 of study I and were
53
not copied here. ?-CIT uptake was significantly lower in PD patients than in
patients with DIP, essential tremor or dystonia both in the whole striatum or in
the putamen and in the caudate nucleus. The uptake to the whole striatum or
to the caudate and putamen was similar in the patients with DIP, dystonia,
essential tremor, and psychogenic parkinsonism.
In the P+ and DLB groups the DAT density was low and the striatal ?-CIT
uptake ratios overlapped with those of the PD group. No significant difference
was found between these groups. Some studies have suggested there may be
difference in the caudate:putamen ratio between PD and P+ or DLB groups,
since in PD the degeneration of the projections to the putamen predominates
and projections to nucleus caudatus are relatively spared compared to PSP or
MSA, in which the striatum may be more uniformly affected. Many have failed
to find a difference 78, 79, 81, 359. Among our patients the caudate:putamen ratio
was highest in the PD group but it was not significantly different from P+ or
DLB groups (data not shown). Also interstriatal asymmetry seemed to be more
pronounced in PD patients but did not allow differentiation of these disorders,
in line with most previous studies 78, 79, 82, 84.
Thus, by using 123I-?-CIT SPECT only, PD, PSP, MSA and DLB can be
differentiated from essential tremor and DIP, but not reliably from each other.
Recently some studies have proposed that quantification of midbrain DAT
signal, in addition to striatal, might add the value of ?-CIT SPECT in the
differential diagnostics between PD and P+ 360, 361.
The striatal uptake of ?-CIT in the vascular parkinsonism (VP) group was
variable (range 3.6 – 6.3) and the mean DAT density was between that found
in psychogenic parkinsonism, essential tremor, dystonia, drug-induced
parkinsonism and in the PD group. In VP the mean ?-CIT uptake ratios in the
whole striatum, caudate and putamen were significantly higher than in PD
patients but lower than in the patients with psychogenic parkinsonism. (Fig 5)
In half of the cases ??CIT uptake was within normal range and below the
normal range in the rest. Gerschlager et al have suggested VP may be
differentiated from PD using ?-CIT SPECT 92. However, closer inspection of
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their data also shows overlap between normal and pathological range.
Consequent results of FP-CIT studies on DAT density in VP patients have been
conflicting 93, 94.
Remarkable interstriatal asymmetry of DAT density, more typical to PD, could
also be seen in some of our patients with VP. A vascular lesion was seen in the
corresponding basal ganglia region in the MRI or CT scans of those
asymmetrical cases. In patients with degeneration of deep white matter
without focal basal ganglia lesions uptake was essentially normal. Thus,
differentiating an extrapyramidal syndrome caused by a focal striatal vascular
lesion from PD by means of 123I-?-CIT SPECT is not reliable without CT or MRI.
As white matter degeneration in the absence of striatal lesions does not seem
to result in a significant decrease in DAT density, 123I-?-CIT SPECT seems to
differentiate PD from VP in such cases.
It is of note that DAT imaging in drug-induced parkinsonism (DIP) has been
reported previously in only a small number of cases. Mostly normal FP-CIT
uptake indices in small groups of DIP patients have been reported. ?-CIT
SPECT in DIP has not been reported at all. We confirmed the previous FP-CIT
results of normal indices with ?-CIT SPECT in this patient group. In some
patients with irreversible DIP, diminished DAT density has been found,
suggesting possible exacerbation of underlying neurodegenerative
parkinsonism in these patients 95-97. Such cases were not found among our
patients.
In our patient material, the role of 123I-?-CIT SPECT was important in the
diagnosis of some patients with DIP, some cases with psychogenic symptoms,
and some patients with atypical essential tremor.
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Figure 5. Striatal 123I-?-CIT uptake in different patient groups
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1.2 Sensitivity and specificity for PD are influenced by age
Sensitivity and specificity were analysed to address the question how 123I-?-
CIT SPECT differentiates idiopathic PD form other conditions.  The sensitivity
and specificity in PD diagnosis in both the contralateral striatum (as whole) and
the contralateral putamen were 98.9 % and 80.5 %, respectively. The uptake
ratios in the contralateral striatum and putamen gave better sensitivity and
specificity than those in the caudate nucleus or ROIs on the ipsilateral side.
(Table 5)
Table 5. Sensitivity and specificity of 123I-?-CIT SPECT in the diagnosis of PD
ALL <55 YEARS ?55 YEARS
Sensitivity
(%)
Specificity
(%)
Sensitivity
(%)
Specificity
(%)
Sensitivity
(%)
Specificity
(%)
CONTRALATERAL
STRIATUM
98,9 80,5 100 100 98,4 68,5
IPSILATERAL
STRIATUM
93,5 79,3 100 92,9 92,2 70,4
CONTRALATERAL
CAUDATUS
93,5 74,7 100 96,4 90,6 63,0
IPSILATERAL
CAUDATUS
92,4 74,7 100 89,3 93,8 59,3
CONTRALATERAL
PUTAMEN
98,9 80,5 100 100 100 68,5
IPSILATERAL
PUTAMEN
96,7 81,6 100 96,4 96,9 72,2
The specificity was remarkably higher in subjects younger than 55 years than
in the subjects older than 55 years. In patients <55 years, both sensitivity and
specificity were 100 % when the contralateral striatal/cerebellar uptake ratio
cut-off was set at 4.5 and also 100% in the contralateral putamen with the
putaminal/cerebellar cut-off value of 3.1.
In patients >55 years the sensitivity of the contralateral striatum was 98.4%
and specificity 68.5% using the same cut-off value of 4.5.  Uptake measured
from the contralateral putaminal ROI yielded 100% sensitivity and 68.5%
specificity (cut-off 3.9). The cut-off age limit of 55 years was arbitrary and
best divided the material into good and poorer specificity.
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The age-dependent difference in the diagnostic accuracy of ?-CIT is likely
explained by different distribution of diagnoses in the old and in the young.
The age-related decline in ??CIT uptake was in this material 4 % per decade.
This decline, however, is not high enough to affect specificity. As the diagnoses
that diminish specificity and are present in the older population  – P+, VP and
DLB – have ?-CIT uptake ratios similar to those of PD, using age-corrected
values would not increase specificity. In younger subjects VP and DLB are rare.
It is likely that in a larger sample of younger patients cases of abnormal ?-CIT
uptake with other diseases than idiopathic PD would exist. However, our result
suggests that in real life the accuracy of ?-CIT in this group is expected to be
close to 100%. A patient younger than 55 with extrapyramidal symptoms is
very likely to have PD if reduced DAT density is found in the striatum.
However, the majority of patients with suspected nigrostriatal pathology are
older than 55.
To be able to exclude or show presynaptic nigrostriatal degeneration (including
PD, P+ and DLB) as such and differentiate these conditions from conditions
without nigrostriatal presynaptic pathology, e.g. DIP, essential tremor,
psychogenic parkinsonism, Alzheimer’s disease and normality, is also of value.
In differentiating conditions with known presynaptic pathology from those
without, the specificity of ?-CIT SPECT would be better than in PD diagnosis,
but the presence of VP especially in older age would diminish the specificity
also in this setting.
1.3 Correlation of ?-CIT with age and severity of symptoms
?-CIT uptake correlated negatively with age (r=-0.39, p<0,01) in non-
parkinsonian subjects (psychogenic parkinsonism, essential tremor, dystonia
and drug-induced parkinsonism). The age-related decline in ?-CIT uptake was
around 4 % per decade in this material, which is concordant with previous
reports 53, 71, 362.  In PD, the nigrostriatal degeneration caused by the disease
process is undoubtedly more prominent that age-associated nigrostriatal
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degeneration.  Hence, the correlation between age and reduction in DAT
density was not significant in the PD group (r=-0.18 p=0.08).
In PD patients the decrease in striatal ?-CIT binding correlated significantly
(p<0.01) with symptom severity. The correlation between the patients’ Hoehn
and Yahr stage and ?-CIT uptake was significant in the whole striatum as well
as in the putamen and caudate ROIs on both the contralateral and ipsilateral
side. Striatal ?-CIT uptake correlated also with the patients’ Schwab & England
scores in all ROIs.  The correlations with Hoehn-Yahr and Schwab-England
were constantly mildly stronger in the ipsilateral side than in the contralateral
side. Thus, the better-preserved striatum seemed to determine the patient’s
functional capacity rather than the more severely affected side. (Data not
shown.)
?
In patients with unilateral parkinsonism (Hoehn-Yahr stage I) the reduction in
?-CIT uptake was more prominent in the contralateral side, but the average
ipsilateral DAT density was also clearly decreased (–37% compared to the
group with psychogenic parkinsonism).  Thus, 123I-?-CIT SPECT is able to
detect PD in preclinical phase and may, therefore, be used in clinical trials to
detect PD very early or even presymptomatically, as a more available and
cheaper alternative for PET. Especially in the future, when neuroprotective
agents hopefully will be available for clinical use, this may be important for at-
risk individuals. Here we also used 123I-?-CIT SPECT as a part of PD patient
selection for the genetic studies.
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2. APOE, COMT and parkin genes in sporadic PD (II)
2.1 APOE in PD
APOE ?2/3/4 polymorphism in PD risk
In our Finnish case-control dataset we did not find any association between
APOE ?2/3/4 polymorphism and PD. Both allele and genotype frequencies were
similar in cases and controls (Table 6).
Previously both ?4 and ?2 have been suggested to increase the risk of PD in
some studies 214, 272-274, 363, 364 while many groups including ours have found no
association 216-220, 365-367. At present it is not clear, whether the initial positive
findings have been true or false positives. If they have been true, the
discordance between studies may be due to genetic heterogeneity between the
populations studied. As PD constitutes a spectrum of symptoms, the clinical
features tend to vary from study to study.
The development of dementia, Alzheimer-type neuropathology or the amount
of cortical LB’s in PD patients have also been proposed to associate with the ?4
allele 215, 279, 368-370. None of the PD patients included in our study were
demented at the time of recruitment. It is possible that the contribution of
APOE, or a gene in its vicinity, is different in striatal and cortical pathologies.
APOE ?2/3/4 polymorphism and age-of-onset of PD
?4 allele has also been suggested to lower age at onset (AAO) of PD 274, 276, 277.
The AAO of all our patients was not precisely known. However, we had 11
early-onset PD patients in our material who definitely had AAO ? 45 years.
Among them, 4 (36%) had ?2/?3, 4 (36%) ???????and 3(27 %) ??????genotype?
Frequency of ??/?? genotype was similar to that in the rest of our patients and
in the controls (see table 6). Thus, ?? was not overrepresented in young-onset
cases. Frequency of the ??????genotype?was somewhat higher than expected in
our early-onset patients (36% vs 10 % in controls). Maraganore et al 218 had a
similar finding, but our group of early-onset patients is too small to draw any
conclusion.
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APOE promoter and enhancer polymorphisms (unpublished data)
APOE promoter (Th1/E47cs, -219 G/T) and enhancer (APOE intron 1 enhancer
element, IE1, +113 G/C) polymorphisms have also been reported to modify
the risk of Alzheimer’ disease 271, 371-374. However, it has remained unclear
whether the effects of these polymorphisms are independent, by modifying the
level of APOE expression, or reflect LD with APOE ?2 and ?4 alleles.
Myllykangas et al 271 studied APOE haplotypes using these above-mentioned
polymorphisms in ?3 homozygous subjects to control the effect of LD with the
predisposing ?4 and protective ?2 alleles and found that the effects of these
polymorphisms were seen independently of the e2 and e4 alleles. In their
study on neuropathologically verified Alzheimer’s disease, the frequencies of
the –219T-?3 and +113C-?3 haplotypes were significantly lower, and -219G- ?3
and +113G- ?3 higher in patients compared to controls.
Association between –219 G/T polymorphism and PD has been studied in only
one study 375 and neither +113G/C polymorphisms nor APOE haplotypes have
been studied in PD patients. We genotyped these polymorphisms and
constructed APOE haplotypes (unpublished data), and found allele and
genotype frequencies of these markers very similar in our PD and control
groups (table 6). Neither were APOE haplotypes associated with PD. The two-
point haplotype data on ?3 homozygous subjects are presented in table 7. Also
3-marker haplotypes with markers –219G/T – +113G/C – APOE were analysed
with HAPLO software both in the whole material and also in ?3 homozygotes.
Haplotype distributions were similar in cases and controls (HAPLO p=1.000,
data not shown).
The risk of Alzheimer’s disease is strongly associated with APOE alleles, with ?4
increasing and ?2 decreasing susceptibility 164, and the effect of different ?3
haplotypes has been shown 271.  Since Alzheimer’s disease and PD are both
neurodegenerative diseases and they share some neuropathological features
24-26, 376, common neuropathological mechanisms for these disorders have been
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investigated. Based on previous and the results presented here, neither APOE ?
polymorphism nor the APOE region haplotypes are a common denominator.
Although APOE region does not seem to have a major role in PD susceptibility,
its role in clinical subgroups and as an age-of-onset modifier deserves further
study.
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Table 6. APOE, -219G/T and +113G/C polymorphisms in PD patients and controls
APOE
PD patients Controls
n f n f
?2 21 7 % 22 8 %
? 3 222 76 % 196 72 %
? 4 51 17 % 56 20 %
?? 294 274
?2=1,17 2 df p=0,56
?2/?2 1 1 % 1 1 %
? 2/?3 16 11 % 14 10 %
? 2/?4 3 2  % 6 4 %
?3/?3 83 56 % 70 51 %
? 3/?4 40 27 % 42 31 %
?4/?4 4 3 % 4 3 %
? 147 137
? 2=1,41 3 df p=0,70 (rare events (2/2, 2/4, 4/4) were here pooled for the ?2 test)
-219 (Th1)
PD patients Controls
n f n f
T 116 39 % 114 42 %
G 178 61 % 160 58 %
? 294 274
? 2=0,27 1 df p= 0,60
TT 21 14 % 21 15 %
TG 74 50 % 72 53 %
GG 52 35 % 44 32 %
? 147 137
? 2=0,34 2 df p=0,84
+113 (IE1)
PD patients Controls
n f                   n f
C 70 24 % 68 25 %
G 224 76 % 206 75 %
? 294 274
? 2=0,08 1 df  p=0,78
CC 10 7 % 6 4 %
CG 50 34 % 56 41 %
GG 87 59 % 75 55 %
? 147 137
? 2=1,88 2 df p=0,39
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Table 7. APOE haplotypes in ?3 homozygous PD patients and controls (unpublished
data)
Patients Controls
-219G/T-??3haplotypes n f N f   %
T-??3 55 33 % 46 33 %
G-??3 111 67 % 94 67 %
? 166 140
?2=0,00 1 df p=0,96
-219-??3genotypes n f n f
T-??3/T-??3 10 12 % 6 9 %
T-??3/G-??3 35 42 % 34 49 %
G-??3/G-??3 38 46 % 30 43 %
? 83 70
?2=0,86, 2 df, p=0,65
+113G/C-??3haplotypes n f n f
C-??3 55 33 % 45 32 %
G-??3 111 67 % 95 68 %
? 166 140
?2=0,03, 1 df, p=0,85
+113-??3 genotypes n f n F
C-??3/C-??3 10 12 % 5 7 %
C-??3/G-??3 35 42 % 35 50 %
G-??3/G-??3 38 46% 30 43 %
?? 83 70
?2=1,51, 2 df, p=0,47
2.2 COMT polymorphisms in PD
The roles of COMT enzyme in catechol (including dopamine) metabolism and
detoxication prompted us to study the possible association of COMT gene with
PD. Val158Met polymorphism encoded by a G to A polymorphism in the
corresponding codon in exon 4 of COMT gene determines the high and low
activity forms of COMT enzyme 280.
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No association of this Val158Met and PD was found: alleles and genotypes
were equally distributed in PD and control groups (Table 8). We also studied
another coding polymorphism rs6267 (Ala72Ser). An association was not found
with this polymorphism (Table 8). Rs6270 was not polymorphic in our patients
or controls.
COMT gene has been studied as an interesting candidate gene in PD because
of its biological function. The results of its association with PD are conflicting
227, 229, 231, 282. The fact that some studies have found Met allele and others Val
to associate with PD, while many like us have found no association, is
consistent with the conclusion that these COMT variations likely have no role in
PD susceptibility. COMT Val158Met polymorphism’s impact on treatment
response to antiparkinsonian medication has also been studied, but no effect
has been detected 377-380.
Table 8. COMT Val158Met and rs6267 polymorphisms in PD and controls
PD patients Controls PD patients Controls
COMT alleles N (%) N (%) COMT genotypes N (%) N (%)
Val/Met(G/A)
Val 131 (45 %) 133 (49 %) Val/Val 30 (20 %) 31 (23 %)
Met 163 (55 %) 141 (51 %) Val/Met 71 (48 %) 71 (52 %)
? 294 274 Met/Met 46 (31 %) 35 (26 %)
?2=0,9 1 df, p=0,34 ?? 147 137
? 2=1,16, 2 df, p=0,56
rs6267 rs6267
G 284 (97 %) 263 (96 %) GG 137 (93 %) 126 (92 %)
T 10 (3 %) 11 (4 %) GT 10 (7 %) 11 (8 %)
? 294 274 TT 0 0
? 147 137
? 2=0,15 1 df, p=0,70 ? 2=0,16, 1 df, p=0,69
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2.3 Parkin coding polymorphisms in PD
Parkin mutations are the most common cause for young-onset recessive PD.
More than twenty different mutations have been found in this large gene with
12 exons spanning about 1.3 Mb of genomic DNA. Associations of coding
polymorphisms of parkin to PD susceptibility have been suggested in Asian and
European populations 203, 207. In Finland, 22 patients with familial PD have been
screened for eight parkin mutations but no mutations have been found 202.
Coding polymorphisms of parkin have not been previously investigated in
Finnish patients.
Wang et al 203 reported first in 1999 parkin polymorphisms in Japanese
sporadic PD. In their study the frequency of Arg366Trp Trp-allele was
significantly (1.2 vs 4.4 %) lower in patients than in controls. This
polymorphism was expected to alter the conformation of the parkin protein
from ?-helix to ?-sheet, and thus possibly affect the protein function.
Ser167Asn and Val380Leu were not associated with PD in that study.
We studied the same coding polymorphisms in our Finnish material, but no
associations with PD were found. Arg366Trp (nt1197C?T in exon 10) was not
at all polymorphic in our cases and controls. The allele and genotype
frequencies of Ser167Asn (nt601G?A in exon4) and Val380Leu (nt1239G?C in
exon 10) were similar in cases and controls (all p-values >0,50, Table 9).  In
our 11 EOP patients with AAO ? 45 y the frequency of C-allele (Leu380) was
higher than in the rest of our patients and controls (41% vs. 15 and 17.5%).
However, this is probably a chance finding due to a small N of our EOP group.
A European study following ours has found association of Val380 and sporadic
PD 207, and Leu380 has been discussed as possibly protective. Results in a later
European study have supported the possible protective effect of Leu380 201.
Val380Leu has been associated with sporadic PD in a Central European study,
but only in early-onset cases, and the associated allele has not been clearly
specified 381. Even though in Asian populations Asn167 has shown association
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to PD 382, 383, no European study has found association between Ser167Asn and
PD 201, 204, 207, 261, 381.  Thus, these polymorphisms do not seem to have any
major role role in the susceptibility to sporadic PD in Finland. However, the
possible role of Val380Leu in predisposition to PD needs further study,
especially in EOP patients.
It is of note that parkin allele frequencies differ remarkably between Asians
and Caucasians, also demonstrated by a recent study that included a meta-
analysis of the frequencies of these polymorphisms 384. For example, Asn167 is
present in about 40% of Asians 203, 385, but substantially more rare in our
Finnish subjects (0.5-1%) and in other Europeans (~2%) 207, 261, highlighting
the importance of cases and controls being ethnically matched.
Table 9. Parkin coding polymorphisms in PD patients and controls
PD patients Controls PD patients Controls
Parkin alleles N (%) N (%) Parkin genotypes N (%) N (%)
Ser167Asn(G/A) Ser167Asn(G/A)
G 291 (99 %) 272 (99 %) GG 144 (98 %) * 135(98,5%)
A 3 (1 %) 2 (1 %) GA 3 (2 %) 2 (1,5 %)
?? 294 274 AA 0 0
P=0,53 (Fischer’s exact test) ? 147 137
p=0,53 (Fischer’s exact test)
Val380Leu(G/C) Val380Leu(G/C)
G 250 (85 %) 226(82,5%) GG 106 (72 %) 94 (69 %)
C 44 (15 %) 48 (17,5 %) GC 38 (26 %) 38 (28 %)
? 294 274 CC 3 (2 %) 5 (4 %)
? 147 137
? 2=0,68, 1df, p=0,41 ?2=0,87, 2df, p=0,65
* Note that allele frequencies of Ser167Asn are correct here but opposite (incorrect) in II
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3. DJ-1 IN SPORADIC PD (III)
In 2003, Bonifati et al reported two loss-of-function mutations in DJ-1 to be
the cause for PARK7, a rare form of autosomal recessive early-onset
parkinsonism 155. A large deletion segregated with PD in a Dutch family, and a
homozygous missense mutation in exon 7 (L166P) in an Italian family.
As variation in the genes of familial PD may also affect susceptibility to the
more common sporadic PD, we chose to test association of DJ-1 and PD in our
case-control material. Because one line of hypotheses on the pathogenesis of
PD involves oxidative stress, the putative role of DJ-1 in oxidative stress
protection also makes it an interesting candidate gene. Common variation
within the promoter regions of parkin and ?-synuclein are suspected to
increase the risk for PD 348, 386. Therefore, of particular interest was an 18 bp
insertion/deletion variant in the promoter region of DJ-1 (g.168_185del). We
also tested polymorphisms in the promoter and intron 5 of DJ-1 in 95 North
American samples to study LD across the DJ-1 gene.
No significant differences were found in the allele and genotype frequencies
between the patients and the controls (Table 10). The distribution of
genotypes was at Hardy-Weinberg equilibrium. Linkage disequilibrium (LD)
was observed between the alleles of the g.168_185del and g.213G>T
promoter polymorphisms (D' = 0.98 ?2=201.4 1 df p< 0.0001) and between
the promoter (g.168_185del) and IVS5+30T>G in intron 5 (D'=0.76 ?2=39.5 1
df p< 0.0001).
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Table 10. DJ-1 Exon 1 Ins/Del 168_185 polymorphism in PD and controls
PD PATIENTS
n* (%)
CONTROLS
n* (%)
ALLELES
Ins 187 (69 %) 182 (71 %)
Del 85 (31 %) 76 (29 %)
?2=0.20, 1 df, p=0.65
GENOTYPES
Ins/Ins 64 (47 %) 63 (49 %)
Ins/Del 59 (43 %) 56 (43 %)
Del/Del 13 (10 %) 10 (8 %)
?2=0.29,  2 df, p=0.86
*Genotyping was not successful in 11 patients and 8 controls.
g.168_185del, a deletion variant within the promoter region of DJ-1 could be
potentially functional due to its localization 168 bp after the transcriptional
activation site 387. However, we did not find any association between this
polymorphism and PD. Since strong LD was observed across the gene, it
seemed unlikely that analysis of further polymorphisms would produce a
positive association with a common predisposing allele in our sample from the
homogenous Finnish population.
Our DJ-1 analysis was performed very soon after the report by Bonifati et al
155. We provided preliminary evidence that common variation within DJ-1 does
not act as a risk factor for PD, but recommended that comprehensive analyses
of variation within DJ-1 in several populations would be required in order to
fully assess the role of this gene in the predisposition to sporadic PD. Since
then, other studies with other populations have not found an association
between DJ-1 and sporadic PD 102, 199, 200, 388. Since DJ-1 mutations among
familial and early-onset PD are very rare 102, 199, the overall contribution of
DJ-1 in PD susceptibility seems to be small.
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4. POLG1 VARIANTS IN PD (IV-V)
A considerable amount of evidence has proposed that mitochondria play a role
in the pathogenesis of PD 298.  Mutations in the gene POLG1 encoding
mitochondrial DNA polymerase gamma (POLG) lead to secondary defects in
mtDNA and subsequent defects and deficiency of the respiratory chain.
Parkinsonism co-segregated with POLG1 mutations in families with progressive
external ophthalmoplegia (PEO) 316. Early-onset parkinsonism in two sisters,
who had a history of migraine and anxiety, was also found to result from
compound heterozygous POLG mutations. In addition to parkinsonism, these
patients had axonal, predominantly sensory neuropathy, but not PEO 320.
These findings encouraged us to study the possible role of POLG gene in
sporadic idiopathic PD.
POLG1 polyglutamine tract variants in Finnish PD patients
In POLG polyglutamine (polyQ) tract, encoded by a CAG repeat in exon 2, the
most common allele lengths are 10CAG (denoted here 10Q, 86-90%) and 11Q
(6-9%) 389-391. These two most common repeat lengths were defined as the
“normal” reference alleles and their frequency was compared to the frequency
of all other alleles (denoted as non-10/11Q alleles).
The polyQ alleles and their frequencies are presented in table 11. We found
significantly increased frequency of exon 2 polyQ tract non-10/11Q length
variants (6Q-9Q, 12Q-14Q, 4R+9Q) in our PD patients (10%) compared with
our spouse controls (3.5%; p=0.003), and population controls (4.3 %;
p=0.001).  Thus, the non-10/11Q alleles were clearly overrepresented in the
PD patient group. Our data indicates that POLG polyQ variation may influence
predisposition to PD.
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Previously a small study with 22 PD patients failed to find association between
POLG polyQ repeat and PD 226. The shortcomings of their study were a material
too small to exclude association of a gene and a multifactorial disease, and
polyacrylamide analysis of the repeat length, which fails to detect polyQ alleles
with amino acid substitutions, such as 4R+9Q (=Q43R). In another study,
analyzing polyQ and selectively exons 7,8,16,18, and 21 in 140 PD patients, no
PD-specific changes were found 225. However, they also used electrophoresis
for polyQ analysis and dHPLC for part of sequence analysis, both of which may
fail to detect some sequence changes.
Table 11. POLG1 exon 2 polyQ alleles in Finnish PD patients and controls
PolyQ allele PD
PATIENTS
n=140
SPOUSE
CONTROLS
n= 128
POPULATION
CONTROLS
n=516
n f (%) n f (%) n f (%)
RRRQQQQQQQQQQQQQQQQQPQQPQ 14Q   2   0.2
RRRQQQQQQQQQQQQQ-QQQPQQPQ 13Q 2   0.7
RRRQQQQQQQQQQQQ--QQQPQQPQ 12Q 7   2.5   3   1.2  16   1.5
RRRQQQQQQQQQQQ---QQQPQQPQ 11Q 15   5.4  15   5.9  88   8.5
RRRQQQQQQQQQQ----QQQPQQPQ 10Q 237  84.6 232  90.6 900  87.2
RRRQQQQQQQQQ-----QQQPQQPQ 9Q 13   4.6   5   1.9  17   1.6
RRRQQQQQQQQ------QQQPQQPQ 8Q 3   1.1   4   0.4
RRRQQQQQQQ-------QQQPQQPQ 7Q
RRRQQQQQQ--------QQQPQQPQ 6Q 1   0.4   1   0.4   3   0.3
RRRRQQQQQQQQQ----QQQPQQPQ 4R+9Q 2   0.7   2   0.2
?? 280      256   1032
POLG1 haplotype analysis
Four-locus analysis with markers rs2238297 C/T, L752L C/T, rs2302084 A/G
and rs3087374 G/T (Q1236H) found six POLG haplotypes with a frequency >
1%. These haplotypes were not significantly associated with PD. Their
frequencies in the PD/control groups were 0.50/0.47, 0.31/0.31, 0.10/0.08,
0.04/0.04, 0.03/0.04,and 0.04/0.02 (global p > 0.1; individual
haplotype p-values > 0.08).  We analyzed the four above-mentioned SNPs
together with the CAG-repeat alleles to test whether the association of the CAG
repeat (polyQ) alleles with PD is influenced by their haplotype background.
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One haplotype (9Q-CCAG) had an increased frequency among PD patients
compared to spouse controls (4.9% vs. 1.3%). In SNPHAP analysis this
particular 9Q-haplotype was found in all 13 patients who carried 9Q and in 3
spouse controls out of 5 carrying 9Q (?2 = 4.93, 1 df, nominal p= 0.026),
while 9Q-allele alone, ignoring haplotype background, did not show a
difference (?2 =2.49, 1 df, p=0.11). The significance of this haplotype finding
remains uncertain due to the small number of these 9Q haplotypes; it may be
a chance finding and needs to be confirmed in other studies.
POLG1 missense variants
A novel missense mutation S1230F was found in one PD case, but in none of
the spouse controls. However, the patient’s 95-year-old sister who does not
have PD had the same mutation, suggesting that it is a neutral variant.
Three previously reported common coding-region polymorphisms (Q1236H,
E1143G, K317K) were found in similar frequencies in PD patients and spouse
controls (all p-values >0.2).
Y831C mutation has previously been reported as the possible culprit in an
Italian family with parkinsonism, hypogonadism, and neuropathy 317. Y831C
was present in one of our PD patients but also in 5 controls. The controls
carrying this variant were born in years between 1924 and 1946 and already
have advanced age but have not had neurological symptoms requiring contact
to neurological health services, except one woman who was diagnosed with
tension type headache. Therefore, our results argue against Y831C’s
pathogenic role 317. It is likely that Y831C is a neutral polymorphism.
Clinical features of the patients with POLG1 variants
Our patients were collected to represent idiopathic sporadic PD, excluding
atypical and familial cases. None of our 14 patients carrying rare non-10/11Q
alleles, missense variants, or both had eye movement abnormalities or ptosis,
which are typical features of POLG1-associated PEO-disease. One patient
carrying 4R+9Q (Q43R), whose initially typical parkinsonism presented at the
72
age of 54, later developed an atypical syndrome including severe
laryngospasms, urinary incontinence, cervical dystonia and brisk reflexes. He
died at the age of 62 years. Other patients have not shown atypical features in
7-15 years follow-up from the onset of PD symptoms.
Even though several studies have now reported parkinsonism as a part of the
disease spectrum in POLG-associated disease with PEO-type features, ataxia,
or neuropathy 316, 320-322, association of POLG variation to idiopathic PD has not
been previously found. The present data support a role for POLG polyQ
variants in idiopathic sporadic PD in Finland. To assess the global role of POLG
in PD, studies in other populations are needed.
POLG polyQ variation in North American PD patients and controls (V)
Our intriguing results showing increased amount of rare non-10/11Q POLG
polyQ length variants in Finnish PD patients compared to controls prompted us
to carry out a replication study on the polyQ variation in a larger sample of
North American PD patients (n=652) and controls (n=292). PolyQ allele and
genotype frequencies were similar in early (?45 years) and late-onset patients
(AAO > 45 years). Neither were polyQ alleles or genotypes in patients with a
positive family history for PD different from those patients without (Data not
shown). The whole patient material was therefore used for comparisons with
the controls. The POLG1 polyQ genotypes are presented in table 12. Allele
frequencies of the US PD patients and US controls, and for comparison,
literature controls are presented in table 13.
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Table 12. POLG1 exon 2 polyQ  genotypes
 US PD PATIENTS
N=652
US CONTROLS
N=292
PolyQ
GENOTYPE
n f (%) n f (%)
6Q/11Q 1 0,2 0 0
7Q/10Q 7 1,1 0 0
7Q/11Q 1 0,2 1 0,3
7Q/12Q 1 0,2 0 0
7Q/14Q 1 0,2 0 0
8Q/10Q 5 0,8 1 0,3
8Q/11Q 0 0 1 0,3
9Q/10Q 11 1,7 7 2,4
9Q/12Q 1 0,2 0 0
10Q/10Q 443 67,9 225 77,1
10Q/11Q 133 20,4 44 15,1
10Q/12Q 31 4,8 10 3,4
11Q/11Q 6 0,9 1 0,3
11Q/12Q 4 0,6 2 0,7
12Q/12Q 2 0,3 0 0
4R+9Q/10Q 4 0,6 0 0
4R+9Q/11Q 1 0,2 0 0
Based on previous literature on allele frequencies and our previous study on
Finnish patients, lengths 10Q and 11Q were considered common, neutral
alleles, and other alleles as rare variants (non-10/11Q), and the frequencies of
the 10/11Q and non-10/11Q alleles were compared in PD patients and
controls. Non-10/11Q alleles (6Q, 7Q, 8Q, 9Q, 12Q, 13Q, 14Q, and 4R+9Q)
were more common in PD patients (5.8 %) than in controls (3.8 %), in
accordance with our previous study on Finnish patients. However, this
difference did not reach statistical significance (two-tailed p=0.07; OR 1.6,
95% CI 0.96-2.53). Thus, our hypothesis based on the previous Finnish results
was not confirmed at a statistically significant level. Comparison to a larger set
of 1541 controls confirmed the lack of significant association in this setting
(table 14).
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Table 13. POLG exon 2 polyQ alleles in the present study and in literature
controls
THE PRESENT STUDY LITERATURE CONTROLS
US PD
PATIENTS
n=652
US
CONTROLS
n=292
FINNISH
CONTROLS*
n=644
MIXED
CAUCASIAN
CONTROLS #
n=605
ALL
CONTROLS
POOLED
n=1541
PolyQ
allele
6Q
7Q
8Q
9Q
10Q
  11Q
12Q
13Q
14Q
4R+9Q
??
n (%)
1 (0,1)
10 (0,8)
5 (0,4)
12 (0,9)
1077(82,6)
152 (11,7)
41 (3,1)
0 (0)
1 (0,1)
5 (0,4)
1304
n (%)
0 (0)
1 (0,2)
2 (0,3)
7 (1,2)
512 (87,7)
50 (8,6)
12 (2,1)
0 (0)
0 (0)
0 (0)
584
n (%)
4 (0,3)
0 (0)
4 (0,3)
22 (1,7)
1132 (87,9)
103 (8,0)
19 (1,5)
0 (0)
2 (0,15)
2 (0,15)
1288
n (%)
0 (0)
2 (0,17)
5 (0,41)
22 (1,8)
1045 (86,4)
99 (8,2)
28 (2,3)
4 (0,33)
1 (0,08)
4 (0,33)
1210
n (%)
4 (0,13)
3 (0,10)
11 (0,36)
51 (1,7)
2689 (87,2)
252 (8,2)
59 (1,9)
4 (0,13)
3 (0,10)
6 (0,19)
3082
 * pooled spouse and population controls from IV
 # from  the doctoral thesis of Rovio A 2006 http://acta.uta.fi/english/teos.phtml?10863
Previous literature on the phenotypic effects of POLG1 polyQ has mostly
defined only the 10Q as the normal reference allele 390, 392. Therefore, we also
analysed whether the frequency of the non-10Q alleles (including also 11Q) in
the PD patients differs from the controls. The 10Q/10Q genotype was
significantly less common in PD patients than in controls (67.9% vs. 77.1%),
and accordingly, other genotypes more common in the patient group (32.1%
vs. 22.1%, ?2=8.09, 1 df, p=0.004). The frequency of the non-10Q alleles was
increased in the PD patients compared to the controls (17.4% in the US PD
group vs. 12.3% in US controls; ?2=7,81, p=0.005; OR 1.50, 95% CI 1.13-
1.99). The association with the non-10Q alleles and PD was also significant in
the more powerful analyses when compared to the literature controls (table
14.)
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Table 14. Association of POLG1 polyQ alleles with PD
US PD
n=652
US
CONTROLS
n=292
FINNISH
CONTROLS#
n=644
MIXED
CAUCASIAN
CONTROLS*
n=605
ALL
CONTROLS
POOLED
n=1541
Alleles n (%) n (%) n (%) n (%) n (%)
10Q+11Q 1229  (94.2) 562  (96.2) 1235  (95.9) 1144  (94.5) 2941  (95.4)
Non-10/11Q 75     (5.8) 22   (3.8) 53    (4.1) 66   (5.5) 141   (4.6)
?? 1304 584 1288 120 3082
?2=3.26, p=0.07 ?2=3.70, p=0.06 ?2=0.10, p=0.75 ?2=2.71, p=0.10
? ? ? ?
Alleles
10Q 1077  (82.6) 512  (87.7) 1132  (87.9) 1045  (86.4%) 2689   (87.2)
Non-10Q 227     (17.4) 72   (12.3) 156   (12.1) 165   (13.6) 393  (12.8)
? 1304 584 1288 1210 3082
?2=7.81, p=0.005 ?2=14.43,
p=0.0001
?2=6.78,
p=0.009
?2=16.37,
p=0.00005
Genotypes n (%) n (%)
10Q/10Q 443 (67.9) 225 (77.1)
Other
genotype
209 (32.1) 67 (22.9)
? 652 292
?2=8.09,p=0.004
“Normal” allele defined either as 10Q + 11Q or 10Q only; variant alleles non-10Q include 6Q-
9Q, 11Q-14Q and 4R+9Q; variant alleles non-10/11Q include 6Q-9Q, 12Q-14Q and 4R+9Q.
?2 and p are from comparisons between the US PD group and the control groups
* from the doctoral thesis of Anja Rovio http://acta.uta.fi/english/teos.phtml?10863  , p.60
# pooled spouse and population controls from IV
Typically in polyQ–associated diseases the repeat expansion is pathogenic.
However, the CAG repeat length variation in the androgen receptor gene is an
example demonstrating that even short and long alleles within the normal range
may be associated with different disease phenotypes 393. The functional effects of
the length variation in POLG1 polyQ repeat are not known, but the polyQ of
POLG1 is relatively stable, as over 80% of people carry the most common length
10Q 390, 391. Also in primates the repeat length is highly conserved, although its
exact length is species-specific, proposing that the length of the tract may be
important for POLG function 390.
Our results indicate that non-10Q variant length alleles of the POLG1 polyQ tract
may increase predisposition to PD, and should motivate more research in this
field. Sequencing-based analysis of POLG1 polyQ repeat in genetic association
76
studies in other populations and materials large enough, as well as studies on the
functional consequences of the POLG polyQ variants are required.
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CONCLUDING REMARKS AND FUTURE PROSPECTS
In this thesis, the usefulness of 123I-?-CIT SPECT in the routine diagnosis of PD
was first evaluated.  Genetic risk factors for sporadic PD were studied in a set of
PD patients and their spouses as controls. 123I-?? -CIT SPECT was used as a part
of patient selection to the genetic study.
Allelic association was not found between sporadic PD and parkin (PARK2) or DJ-
1 (PARK7), mutations in which cause autosomal recessive parkinsonism.
The functional Val158Met polymorphism or another coding polymorphism of
COMT were not associated with the risk of PD. This adds to the conflicting, mainly
negative literature reports.
We are the first to report APOE promoter and enhancer region polymorphisms –
219G/T and +113G/C and APOE ?3 haplotypes in PD. No association with PD was
found. The APOE ?2/3/4 polymorphism was not associated with PD susceptibility
either, even though it modifies risk for Alzheimer’s disease and prognosis of for
example brain trauma.
An association was found between PD and POLG1. First, in our Finnish sample we
found increased amount of rare non-10/11Q length variants of POLG1 exon2 CAG
repeat (polyQ) in PD patients compared to controls (10% vs. 3.5%, p=0.003).
The two most common lengths 10Q and 11Q were initially considered as the
normal reference lengths and alleles 6Q-9Q, 12-14Q and 4R+9Q as rare length
variants, since the summarized allele frequency of 10Q (86-90%) and 11Q is in
different populations around 95 %. Our positive result in Finnish patients
motivated us to perform a larger replication study on POLG1 polyQ length
variation in US PD patients and controls. This study with a higher statistical
power study led to sharpening the definition of the “normal” allele. Also other
studies on other phenotypical phenomena and POLG1 mainly considered 10Q as
the only “normal” allele. The replication study did not confirm the pathogenic role
of the non-10/11Q alleles, but showed that non-10Q alleles (including 11Q) were
significantly more common in patients than in controls (p=0.005). Comparison to
other control groups also showed significant association with PD (p=0.00005).
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Our results strongly suggest that alleles other than 10Q may increase
susceptibility to PD. Mutations in POLG may lead to secondary defects in mtDNA,
and thus mitochondrial dysfunction, suspected in the pathogenesis of PD.
Functional effects of the polyQ length variation are not known.  Large replication
studies are warranted, in addition to studies on the functional consequences of
the POLG1 polyQ variants.
Earlier studies had reported 123I-?-CIT SPECT in selected sets of patients with a
specific movement disorder compared to controls. We studied how useful 123I-?-
CIT SPECT is in the differential diagnosis of PD in a consecutive real-life material
including various movement disorder patients. Our results show that 123I-?-CIT
SPECT may aid in the diagnosis of PD, differentiate between PD and DIP, ET,
psychogenic parkinsonism, and those cases of VP who do not have a striatal
vascular lesion. P+ and DLB patients had reduced uptake similar to that of PD
patients, and thus 123I-?-CIT SPECT cannot help in differentiating these
conditions from PD. However, in the differential diagnosis between DLB and
Alzheimer’s disease 123I-?-CIT SPECT may be helpful. 123I-?-CIT SPECT correlated
with symptoms rather than age and since it was able to detect presynaptic
nigrostriatal defect already in asymptomatic phase (bilateral decrease in uptake
in patients with unilateral PD), 123I-?-CIT SPECT may be used to screen
presymptomatic PD among at-risk individuals.
Since already 60 % of the nigrostriatal neurons are lost at the time of PD
diagnosis, an important challenge is to shift PD diagnosis to an earlier phase of
the disease, especially in the future, when hopefully neuroprotective therapies
will be available. 123I-?-CIT SPECT may be one way to detect PD in
presymptomatic (or at least premotor) stage in at-risk individuals. Also screening
those subjects with possible premotor features of PD, such as hyposmia or REM
sleep behavioural disorder, might be beneficial. Clinical studies are needed to
recognize more symptoms or signs that may precede PD.
So far no biomarkers of PD are available. A future means to detect early PD
might be measuring gene expression signals in the blood. Recently, a study on
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early-stage PD patients found significantly reduced or increased expression in 22
genes in a whole-genome expression chip analysis. Remarkable part of these
genes were involved in the processes relevant in PD, e.g protein folding,
ubiquitin-proteasome system and mitochondrial function 394.
During the years that this thesis was carried out, research and knowledge on the
genetics of PD expanded. Genetic studies have revealed new metabolic routes in
the pathogenesis of PD, for example altered function or amount of SNCA,
disturbances in protein degradation, especially ubiquitination (UCHL1, parkin),
and impaired mitochondrial function (PINK1, parkin, HTRA2/Omi, DJ1, and our
results on POLG1). It is likely that PD results from many different genetic
susceptibility variants with small individual effect interacting with environmental
factors. Hope of finding a single common pathway of pathogenesis for
neurodegeneration in PD may be illusory. PD may not be just one disease:
instead, there may be different neurometabolic subgroups finally leading to
similar clinical and neuropathological outcome. Recognizing these subgroups
would be important in developing preventive or neuroprotective therapy.
Hopefully, in the future, tailor-made neuroprotective therapy could be offered for
each patient according to the patient’s PD subtype.
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APPENDIX
Candidate genes studied in sporadic PD (random order)
1. LRRK2
2. NAT2
3. MTHFR
4. PINK1
5. SCA2
6. MTH1
7. SNCA
8. IL10
9. POLG=POLG1
10. SNCA multipl
11. CYP2D6
12. MAPT =tau
13. ATP13A2
14. GBA
15. UCHL1
16. MTIF1
17. GSTP1
18. GSTM1
19. APOE
20. BDNF
21. LRRK1
22. CARD15/NOD2
23. DJ1
24. NR4A2=Nurr1
25. GRK5
26. POMC
27. SIAH1
28. parkin
29. GCH1
30. TH
31. Sema5A
32. SLC18A2=VMAT2
33. SPR=Sepiapterin
34. CD14
35. FGF20
36. ?1antichymotrypsin=SERPINA3
37. TATA box binding protein
38. Synaptotagmin XI
39. PON1
40. FMR1=FRAXA
41. MAO-A
42. MAO-B
43. NEUROFILAMENT M
44. MCP1 =CCL2
45. CCR-2
46. SCA17
47. SYNPHILIN-1=SNCAIP
48. DAT=DAT1=SLC6A3
49. IRP2=IREB2
50. COMT
51. NEUROFILAMENT L =NEFL
52. NFKB1
53. A2Macroglobulin=A2M
54. ACE
55. hSKCa3
56. TNF-a
57. DRD5
58. IL6
59. TNFR1
60. DCP1
61. BCHE
62. IL-1B
63. IL-1A
64. IL-1R
65. CYP1A1
66. persyn=SNCG=synuclein ?
67. MnSOD=SOD2
68. mt tRNA a4346G
69. DRD2
70. ND2
71. Cu/ZnSOD
72. CAT=catalase
73. DRD3
74. DRD4
75. CYP2E1
76. HTRA2/OMI
77. iNOS =NOS2A
78. PRNP
79. TYROSINASE=TYR
80. ADH1C
81. GSTO1
82. GSTZ1
83. GSTO2
84. DRD1
85. PANK2
86. PASD1
87. ND5
88. ND1
89. ND3
90. ND4
91. SCA8
92. HLA
93. SCA3
94. IFNg
95. EPHX1
96. EPHX2
97. NQO1
98. NQO2
99. 5HTT=SCL6A4
100. ND6
101. CCK
102. ACO2
103. GLO-1
104. PARP1
105. MTR
106. TGFB2
107. PTGS2
108. GCT25D1
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109. NDUFS2
110. NGFB
111. NEGR1
112. ELAVL4
113. CDCP2
114. HTR6
115. PRDM2
116. CYP1B1
117. HNMT
118. ABP1
119. IL1RN
120. PITX3
121. LMX1B
122. OTX2
123. EN1
124. GALNT3
125. NDUFS1
126. USP24
127. USP40
128. RANTES =CCL5
129. CCR5
130. TF =transferrin
131. TFR1
132. HFE
133. FRATAXIN
134. LACTOFERRIN
135. GAP43
136. GSK3B
137. PRKCZ
138. EDEM1
139. VIPR1
140. SIAH2
141. CP =ceruloplasmin precursor
142. WFS1
143. CCKAR
144. PHOX2B
145. ASCL1
146. IL8
147. IL2
148. ADH1B
149. ADH4
150. CASP6
151. ANK2
152. FGF2
153. MGST2
154. CASP3
155. DAP
156. NDUFS4
157. ACSL6
158. HSPA6
159. CSNK1A1
160. HRH2
161. SNCB
162. GRK6
163. CANX
164. CSNK2B
165. HSPA1L
166. HSPA1A
167. HSPA1B
168. VEGFA
169. PLA2G7
170. GSTA4
171. CNR1
172. FABP7
173. ESR1
174. SLC22A1
175. SLC22A2
176. SLC22A3
177. OGDH
178. DDC
179. ABCB1=MDR1
180. PON2
181. DLD
182. CAV1
183. GPR37=PAELR
184. PTN
185. NOS3
186. eNOS
187. nNOS = NOS1
188. EN2
189. SHH
190. NAT1
191. CTSB
192. NDUFB9
193. DNAJA1
194. VCP
195. UBQLN1
196. CTSL
197. NDUFA8
198. TOR1A
199. DBH
200. TFAM
201. CYP2C9
202. CYP2C19
203. SCD
204. NDUFB8
205. GBF1
206. CTSD
207. IGF2
208. INS
209. CCKBR
210. CALCA
211. CNTF
212. FADS1
213. FADS3
214. FTH1
215. CTSF
216. ABRBK1=GRK2
217. NDUFS8
218. PHOX2A
219. RAB6A
220. MMP1
221. MMP3
222. NCAM1
223. HSPA8
224. GRIN2B=NMDAR2B
225. LRP1=A2MR
226. APAF1
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227. MTIF3
228. HTR2A
229. ESR2=ESRB
230. MTHFD1
231. CTSH
232. CYP1A2
233. CSNK2A2
234. HP (haptoglobin)
235. FA2H
236. STX8
237. ACACA=ACC1
238. SUMO2
239. P4HB
240. ADCYAP1
241. CDH2
242. BCL2
243. NDUFS7
244. NDUFA7
245. ICAM1
246. CALR
247. NDUFB7
248. CPAMD8=VIP
249. FTL
250. PRKCG=SCA14
251. CSNK2A1
252. CHRNA4
253. PSMA7
254. SS18L1
255. IFNGR2
256. ADORA2A
257. KCJN6
258. GSTT1
259. ADRBK2
260. YWHAH=14-3-3 eta
261. HMOX1
262. SEPT3
263. NDUFA6
264. NDUFA1
265. FRAXE=FMR2
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